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The emergence of highly pathogenic avian influenza A viruses (HPAI) and their potential 
to cause human infections poses substantial public health threats. Among HPAI, H5 viruses are of 
particular concern given their global spread in avian species, zoonotic infection to humans and the 
high mortality rate in humans. While HPAI H5N1 human infections have typically been reported 
in Asian countries, Canada reported a case of fatal human infection by the HPAI H5N1 virus in 
2014. The genome of the causative virus A/Alberta/01/2014 (H5N1) (AB14 (H5N1)) has been 
reported; however, the isolate had not been evaluated for its pathogenicity in animal models. 
In the first part of my thesis study, I characterized the pathogenicity of AB14 (H5N1) in 
mice and found that AB14 (H5N1) is highly lethal in mice. The virus caused systemic viral 
infection and erratic proinflammatory cytokine gene expression in different organs, including lung, 
spleen, and brain. This study not only provided experimental evidence to complement the specific 
human case report but also established an animal model for HPAI H5N1 virus, which is valuable 
and essential for evaluating vaccine and antiviral candidates against the potential influenza 
pandemics. 
Vaccination is the most effective intervention to prevent possible pandemic outbreaks. The 
conventional egg-based vaccine production strategy takes up to six months for vaccine 
development, during which the antigenically distinct pandemic viruses are allowed to spread in 
the naïve population leading to a rapid disease progression. Traditional inactivated vaccines 
against zoonotic avian influenza viruses often suffer from low immunogenicity due to the intrinsic 
poor antigenicity of avian influenza viruses, or they are poor inducers of cellular immunity. In my 
second part of the study, I aimed to develop a new subunit H5 influenza vaccine to achieve better 
immune protection against HPAI H5N1 virus infection. I expressed and purified hemagglutinin 
(HA) derived from AB14 (H5N1) using both mammalian (m) and bacterial (b) expression systems. 
The purified recombinant proteins were formulated with a proprietary adjuvant (TriAdj); their 
efficacy as vaccine candidates was then evaluated in the mouse model I established in the first part 
of the study. Intramuscular vaccination of two doses of TriAdj-formulated mammalian-expressed 
HA (m-HA/TriAdj) provided full protection against a lethal challenge of AB14 (H5N1) in mice. 
In contrast, bacterially expressed HA with TriAdj (b-HA/TriAdj), b-HA without adjuvant or m-
HA without adjuvant did not result in protection in immunized mice. Furthermore, I analyzed the 
immune responses and found that m-HA/TriAdj elicited significantly higher levels of balanced 
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Th1 and Th2 responses and neutralizing antibody. All of the mice in this group survived a lethal 
AB14 (H5N1) challenge and showed no signs of disease or infection as demonstrated by no loss 
of body weight or detectable virus in the lungs. My results suggest that m-HA formulated with 
TriAdj has the potential to protect against pandemic H5N1 in the event of its cross over to the 
human host. 
Overall, the two parts of this thesis provide an animal model for the HPAI AB14 (H5N1) 
virus and a highly effective vaccine candidate against the HPAI H5N1 virus. Understanding the 
pathogenicity of HPAI H5N1 virus in an animal model and developing the anti-H5 vaccine 
candidate will all contribute to the preparedness for a potential influenza pandemic caused by 
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CHAPTER 1 INTRODUCTION 
1.1 Influenza A virus (IAV) biology 
1.1.1 IAV genome and proteins 
Influenza virus belongs to the family of Orthomyxoviridae, which is composed of seven 
genera, including Alphainfluenzavirus, Betainfluenzavirus, Gammainlfuenzavirus, 
Deltainlfuenzavirus, Thogotovirus, Isavirus, and Quaranjavirus (Hause et al., 2014; Hause et al., 
2013). Most of the seasonal epidemics and outbreaks are associated with influenza A and influenza 
B viruses, whereas influenza C viruses only cause mild or asymptomatic infections in humans 
(Hause et al., 2013; Mosnier et al., 2015; Poon et al., 2016). Additionally, Influenza D viruses have 
not been isolated from humans but from pigs and cows (Hause et al., 2014). Salmon anemia virus 
belongs to the genus of Isavirus, which causes infectious salmon anemia in farmed salmon 
(Aamelfot, Dale, & Falk, 2014). Unlike influenza viruses, which commonly replicate in the 
respiratory tract, Thogotovirus replicates systemically in the vertebrate host and is transmitted by 
ticks (Kochs et al., 2010). Quaranfil virus which belongs to the genus of Quaranjavirus, is also 
transmitted by ticks and is the only virus that could cause human infections in this genus (Presti et 
al., 2009). 
 The IAV contains eight single-stranded negative-sense RNA segments encoding at least 
17 viral proteins. The capacity of one viral segment coding for more than one protein results from 
either splicing or using an alternative open reading frame. In the order of length, the eight segments 
are: polymerase basic 2 (PB2), polymerase basic 1 (PB1), polymerase acid (PA), hemagglutinin 
(HA), nucleoprotein (NP), neuraminidase (NA), matrix protein (M), NS (nonstructural protein) 
(Figure 1.1) (Krammer et al., 2018). In each viral segment, the coding region is flanked by a 
segment-specific non-coding region at both ends.  The self-complementary terminal genomic 
regions of viral genomic RNA (vRNA) could form a double-stranded panhandle structure, which 
serves as the promoter of viral replication. The panhandle structure on each vRNA segment is 
bound to the trimeric RNA dependent RNA polymerase (RdRp) complex comprising the PB2, 
PB1, and PA proteins, while the rest of the segment is encapsidated with multiple NP proteins. 
The vRNA, NP protein, and the three polymerase proteins together assemble into the viral 
ribonucleoprotein (vRNP) complex, which is the minimal functional unit for viral transcription 
and replication (Figure 1.2). Virion core including eight vRNP complexes is surrounded by the 
matrix protein 1 (M1), which lies right underneath a host-derived lipid membrane harboring a large 
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number of spike proteins hemagglutinin (HA) and neuraminidase (NA) at a ratio of approximately 
four to one along with a low abundance of matrix protein 2 (M2) (Figure 1.1) (Palese P, 2013).  
Reprinted from Nat Rev Dis Primers. 4(1), 3 (Krammer et al., 2018) with permission 
Figure 1.1 The structure of influenza A virus.  
The two surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA), and the iron-channel 
protein M2 are anchored on the lipid envelope derived from the host cell membrane, beneath which 
the matrix protein (M1) forms a matrix layer. Within the matrix layer are eight viral 
ribonucleoprotein complexes, each of which comprises one viral RNA genome associated with 
nucleoprotein (NP) and the three polymerases (polymerase basic protein 1(PB1), polymerase basic 




Reprinted from Nature Reviews Microbiology. 13(1), 28 (Eisfeld, Neumann, & Kawaoka, 2015) 
with permission 
Figure 1.2 The influenza vRNP complex.  
Viral ribonucleoprotein (vRNP) complex is comprised of a single-stranded negative-sense viral 
genomic RNA associated with multiple nucleoprotein (NP) and a trimeric polymerase complex 
consisting of polymerase basic protein 1(PB1), polymerase basic protein 2 (PB2), and polymerase 
acidic protein (PA). The 5’ and 3’ end of vRNA forms a partially complementary panhandle 
structure and bind by the polymerase complex at one end of the vRNP filament. The vRNA 
associated with NP is organized into an antiparallel double helix structure with a loop at the 
opposite end of the vRNP filament to the complex of three polymerases. 
 
 
IAV encodes 12 major viral proteins, and they each have diverse functions. Each viral 
polymerase core is a compact of three polymerase units interacting with each other (Hemerka et 
al., 2009; Vasin et al., 2014). PB2 and PA not only play vital roles in viral replication, but also are 
essential in viral mRNA transcription due to their unique roles in catching the cap of host RNAs 
and cleaving the capped RNA off; which is then used in the initiation of viral mRNA synthesis 
(Boivin, Cusack, Ruigrok, & Hart, 2010; Dias et al., 2009; Guilligay et al., 2008; Liang, Danzy, 
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Dao, Parslow, & Liang, 2012). The viral mRNA elongation is catalyzed by PB1, the RNA-
dependent RNA polymerase, which could also replicate vRNA in a primer-independent manner 
by synthesizing complementary RNA (cRNA) acting as replicative intermediate (Fodor, 2013; Te 
Velthuis & Fodor, 2016). PB1 alone has also been shown to be able to transcribe the RNA template 
in vitro (Kawaguchi, Naito, & Nagata, 2005). There is an alternate open reading frame on the PB1 
segment encoding the PB1-F2 protein: an accessory protein expressed in most of the human 
influenza A viruses. Although PB1-F2 is dispensable in viral transcription and replication, it is 
critical in regulating the virus pathogenesis and disrupting the host immune response towards 
influenza viruses by inducing the death of immune cells, interfering with interferon induction, and 
stimulating the secondary bacterial infection (James et al., 2019; Kamal, Alymova, & York, 2017; 
Vidy et al., 2016).  PA segment also encodes a viral protein PA-X by ribosomal frameshift, which 
has been proved to be involved in the degradation of host mRNA in order to reduce general host 
protein expression in virus infected cells. (Chaimayo, Dunagan, Hayashi, Santoso, & Takimoto, 
2018; Jagger et al., 2012). The host shutoff effect of PA-X contributes to the modulation of viral 
pathogenesis and facilitates virus replication (Hayashi, MacDonald, & Takimoto, 2015). 
Besides the three polymerases, NP as an RNA-binding protein is also a major component 
of the vRNP. NP encapsulates the RNA genome, binds to the viral RdRp, and has a vital role in 
viral replication and transcription.  The template-associated NP as an elongation factor is essential 
in completing the processivity of RdRp during the replication of the vRNA (Turrell, Lyall, Tiley, 
Fodor, & Vreede, 2013).  
The primary viral membrane proteins HA and NA are protruding on the surface of the viral 
envelope, which is derived from the host lipid membrane. The genetic and antigenic properties of 
the HA and NA are used to classify the IAV into subtypes. There are 16 HA (H1-H16) and 9 NA 
(N1-N9) subtypes identified in IAVs in aquatic birds (Yoon, Webby, & Webster, 2014). In 
addition, two HA and NA subtypes have been isolated from bats (Tong et al., 2013). The constant 
mutations on HA and NA proteins are referred to as antigenic drift, which is in response to the pre-
existing antibody-mediated immunity in the host due to the selection pressure posted by previous 
natural infections or vaccinations. The direct changes altering the antigenicity of HA or NA of 
currently circulating IAV is known as antigenic shift, and these changes are often due to the 
reassortment between two different strains of the same type of virus, or between two more diverse 
viruses.  (Krammer et al., 2018). Antigenic shift is likely to result in influenza A pandemics 
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because of the lack of pre-existing antibodies in the population to the antigenically distinct 
influenza viruses. Antigenic drift and shift are the two processes responsible for the frequent 
updates of influenza vaccines to ensure the matching of the vaccine strains and the newly emerging 
viruses. Aside from the antigenicity of HA and NA, they each have unique roles in the virus 
lifecycle. Specifically, HA is responsible for the binding to the sialic acid receptor located on the 
cell surface and fusion of the viruses to the host cellular endosomal membrane. The sialidase 
enzymatic activity of NA allows the cleavage of the sialic acids on both host cells and the viral 
glycoproteins, which results in the proper release of the newly synthesized virions and the 
prevention of aggregated nascent virus particles, respectively (Taubenberger & Kash, 2010).  
1.1.2 IAV life cycle 
Influenza virus enters the cells through binding to the sialic acid receptor on the cell surface, 
followed by uptake into the cell through receptor-mediated endocytosis. After the fusion of the 
viral membrane to the host endosomal membrane, the vRNP complexes are released into the 
cytoplasm and are imported into the nucleus, where the viral transcription and replication takes 
place. Viral mRNA is exported into the cytoplasm for viral protein translation, and some nascent 
viral proteins are imported back to the nucleus to assemble new vRNP complexes. Newly-
synthesized vRNPs are exported from the nucleus along with other viral proteins remaining in the 













Reprinted from Nat Rev Dis Primers. 4(1), 3 (Krammer et al., 2018) with permission. 
Figure 1.3 Influenza life cycle. 
Influenza virus enters the cell through receptor-mediated endocytosis, followed by the release and 
the import of viral genome into the nucleus for the transcription and replication of the viral genome. 
Viral mRNAs are exported into the cytoplasm for viral protein translation, and the translated viral 
proteins along with the newly synthesized vRNPs are assembled into new virions. NEP, nuclear 
export protein; NA, neuraminidase; HA, hemagglutinin; M1, matrix protein; M2, membrane 
protein; NS, nonstructural protein; NP, nucleoprotein; PB1, polymerase basic protein 1; PB2, 
polymerase basic protein 2; PA, polymerase acidic protein.  
 
 
1.1.2.1 Entry and endosomal fusion 
IAV initiates the infection by binding of the viral glycoprotein HA to cell surface 
glycoconjugates containing sialic acid residues. This binding might not be sufficient for further 
internalization of the virus particle, because multiple HA-adhering events on the cell surface are 
required for the stable association between influenza viruses and host cells. This insufficient 
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binding event leads the individual HA to “browse” across the neighboring receptors, and this 
“browsing” behavior is referred to as the receptor exchange mechanism of HA.  The receptor 
exchange mechanism mediated by the sialidase activity of NA directly drives the translocation of 
the influenza virus particles on the cell surface between receptors until enough number of HA-
receptor complexes are formed. In this way, the virus is tightly bound to the cell surface (Sakai, 
Nishimura, Naito, & Saito, 2017)  
Influenza viruses’ replication efficiency in specific species depends on their specificity 
towards different sialic acid (SA) linkages. Human influenza viruses have a preference for the 
receptors with α-2, 6-linked SA, while HAs from avian influenza viruses have a higher affinity for 
the α-2, 3-linkage (Matrosovich et al., 2000; Rogers & Paulson, 1983). In agreement with the 
findings of the viral specificity, the α-2, 6-linked SAs are abundant in human tracheal epithelial 
cells, while α-2, 3-linked SAs are presented in the lower respiratory tract. Pigs have similar α-2, 
6-linked and α-2, 3-linked SA distribution as humans in the respiratory tract (Rajao, Vincent, & 
Perez, 2018). In ducks and chickens, α-2, 3-linked SAs mostly exist in the gut epithelium, and both 
2, 6-linked and α-2, 3-linked SAs are presented at the respiratory and intestinal tract in all birds 
(Franca, Stallknecht, & Howerth, 2013; Nelli et al., 2010; Shinya et al., 2006). Mouse, as a 
commonly used laboratory model to study influenza pathogenesis, has α-2, 3-linked SA receptors 
on the apical membrane of the mouse, which greatly resembles the receptor distributions on human 
ciliated airway epithelial cells (Ibricevic et al., 2006). While in the lower respiratory tract, unlike 
the human, mouse showed a significant amount of α-2, 3-linked receptors but few 2, 6-linked 
receptor in the lung (Wasik et al., 2017). The abundance of 2, 3-linked receptor in mice makes it 
an ideal model to evaluate the pathogenesis of influenza viruses of avian origin.  
The expression of avian influenza virus receptor (α-2, 3-linked SA) or human influenza 
virus receptor (2, 6-linked SA) in the human brain also explains systematic diseases associated 
with some influenza infections. Kim et al. described that the majority of neutrons and astrocytes 
in the human cerebral cortex, brainstem, hippocampus, and cerebellum showed expression of both 
avian and human virus receptors (M. Kim et al., 2013). 
The receptor association mediated by HA leads to the endocytosis of the virus particles. 
Once the viruses enter the endosome, the low pH conditions in the endosome lead to a drastic 
conformational change in pre-cleaved HA proteins on the viral surface. The cleavage of HA allows 
the exposure of the fusion peptide, and the fusion peptide inserts into the endosomal membrane 
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upon pH change. Meanwhile, the C-terminus of HA anchors in the viral membrane. The fusion 
peptide aligns antiparallel to the membrane-anchored HA domain and brings the endosomal 
membrane and the viral membrane in close proximity leading to fusion (Bullough, Hughson, 
Skehel, & Wiley, 1994). After the fusion, the low pH condition inside the virus enables the influx 
of H+ ions through the ion channel M2 protein into the virus particle, which results in the release 
of vRNPs to the cytoplasm (Shimbo, Brassard, Lamb, & Pinto, 1996). 
1.1.2.2 Genome transcription and replication 
Once the vRNP complexes are released into the cytoplasm, they have to rely on an active 
nuclear import mechanism due to their large sizes. The import of the vRNPs is adequately and 
efficiently dependent on the nuclear localization signals (NLSs) on NP, although the NLS is 
located in all polymerase proteins. The importin α binds directly to the NLS on NP and then 
recruits importin β to form a complex; importin β docks at the nuclear pore and facilitates the 
translocation of the vRNPs from the cytoplasm into the nucleoplasm (Gorlich, Vogel, Mills, 
Hartmann, & Laskey, 1995). Inside the nucleus, vRNA transcription and replication are 
accomplished by RdRp. The transcription is initiated with the stealing of the 5’-cap, which is 
around 10 to 13 nucleotides in length, from the host noncoding RNAs, preferentially promoter-
associated capped small RNAs and pre-mRNAs, and this process is known as cap-snatching (Gu 
et al., 2015; Koppstein, Ashour, & Bartel, 2015). The cap-snatching process relies on the cap-
binding function of the PB2 protein and the endonuclease function of the PA protein. The 
transcription of vRNA to mRNA depends on the polymerase function of PB1 protein. The 
transcription starts on the 3’ end of the vRNA and elongates until approximately 16 nucleotides 
before the 5’ end, where the polyadenylation signal is generated. One of the widely accepted 
models proposed that RNA polymerase synthesizes mRNA from 3’ to 5’ end and is unable to read 
beyond the poly-uridine stretch due to the spatial hindrance, which results in the addition of poly(A) 
tail at the 3’ end of the newly synthesized mRNA (Palese P, 2013).  
Different from the primer-based initiation mechanism of mRNA synthesis, vRNA 
replication intermediate cRNA is synthesized in a primer-independent process, which relies on the 
accurate complementation of free rNTP to the 3’ end of the vRNA. Nascent cRNA associates with 
newly synthesized polymerases and NP protein to incorporate into the cRNP complex. The cRNA 
then serves as the template to generate progeny vRNA complex (York, Hengrung, Vreede, 
Huiskonen, & Fodor, 2013).  
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1.1.2.3 Genome packaging and budding 
Besides viral polymerase proteins and NP protein, which are imported into the nucleus for 
vRNP assembly, NS1, M1, and nuclear export protein (NEP) are also translocated into the nucleus. 
NEP and M1 play essential roles in  vRNP nuclear export  and prevention of re-import of vRNP 
into the nucleus through blocking the NLS signal on NP protein (Bui, Whittaker, & Helenius, 1996; 
York et al., 2013). Other nascent viral proteins, including HA, NA, and M2, are transported to the 
endoplasmic reticulum (ER), processed by post-translational modification in the Golgi apparatus, 
and translocated to the plasma membrane by translocon, which refers to the protein complex that 
facilitates the translocation of polypeptide across the membrane (Schnell & Hebert, 2003). The 
transmembrane domain of HA and NA both contain the apical targeting information which directs 
the two glycoproteins to the plasma membrane (Mora, Rodriguez-Boulan, Palese, & Garcia-Sastre, 
2002). The export of the vRNP complex is mediated by M1 protein that associates with both the 
vRNP complex and the transmembrane domain of HA and NA. Thus, M1 protein is crucial in 
recruiting the viral components to the viral assembling site at the host plasma membrane (Nayak, 
Hui, & Barman, 2004).  
Upon viral packaging, the precise mechanism of packaging eight vRNPs in each viral 
particle is vital to further viral replication. The widely acknowledged model is the selective 
incorporation model, which suggested that there were unique packaging signals located on the 
coding region and noncoding region at both the 3’ and 5’ end of each vRNA segment; thus every 
virion is able to incorporate a full set of 8 vRNPs (Hutchinson, von Kirchbach, Gog, & Digard, 
2010). Virus budding starts with the outward curvature of the lipid raft region on the plasma 
membrane, where viral HA and NA are located. The final step of viral budding is the scission of 
virion off the plasma membrane.  Besides viral glycoproteins HA and NA, M2 also plays a vital 
role in virus budding and scission. By interacting with M1 protein, M2 is recruited to the viral 
budding site, where the membrane-proximal amphipathic helix domain on M2 alters the membrane 
curvature, and this process further leads to the budding and releasing of the virus particle (Rossman 
& Lamb, 2013).    
 
1.2 IAV HA 
HA is the most abundant glycoprotein in the influenza virus and is responsible for viral 
attachment and subsequent fusion of the viral membrane to cellular membranes. Among the four 
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types of influenza viruses (A, B, C, and D), influenza A viruses are divided into subtypes based 
on the two viral glycoproteins: HA and NA. There are 18 known HA subtypes (H1-H18) and 11 
known NA subtypes (N1-N11). Based on the primary sequence of HA, IAV could be categorized 
into two phylogenic groups, group I and group II , and each  group contains various viral subtypes: 
group I includes H1, H2, H5, H6, H8, H9, H11, H12, H13, H16, H17, and H18;  and group II 
contains H3, H4, H7, H10, H14, and H15 subtypes (Gamblin & Skehel, 2010; Y. Wu, Wu, Tefsen, 
Shi, & Gao, 2014).  
1.2.1 HA structure and antigenic sites  
HA is a trimeric rod-shaped molecule with its C-terminus inserted into the viral membrane. 
The first X-ray crystallographic structure of the HA ectodomain derived from H3N2 virus 
(A/Aichi/68) was solved in the early 1980s and was the largest biological molecule that had a 
resolved structure(Wilson, Skehel, & Wiley, 1981). Crystal structures of numerous HAs of 
different subtypes of influenza A virus have been solved now. Although the amino acid sequence 
similarity is less than 50% between them, the structure and even the function of these HAs are 
unbelievably conservative. Moreover, the structure and function of HA in influenza A and B virus 
is also similar though with only 25% of amino acid sequence identity (Palese P, 2013).   
HA is synthesized as a polypeptide HA0, and the cleavage of HA0 into HA1 and HA2 is 
essential for activating the infectivity of influenza virus, because the cleavage of HA0 exposes 
HA2, which plays a vital role in the virus intake process after absorption (Figure 1.4).  The 
initiation of the HA cleavage occurs extracellularly after the release of viruses from the cells. The 
cleavage of HA is essential for virus infectivity owing to the exposure of the N- terminal fusion 
peptide located at the N-terminus of the HA2 peptide, which allows the fusion between cells and 
viruses during infection (Steinhauer, 1999). HA protein is synthesized as a precursor protein 
(HA0), and it requires to be cleaved at a single arginine or rarely a single lysine site in order to be 
activated for most avian and mammalian influenza viruses (Bottcher-Friebertshauser et al., 2010). 
HA0 is cleaved into two subunits HA1 and HA2, which are linked by a disulfide bond. The 
identified HA activators are trypsin or various trypsin-like proteases, such as plasmin, the tryptase 
Clara in murine bronchiolar epithelial cells, the tryptase from mast cells of porcine lung, and the 
protease from chicken allantoic fluid (Gotoh, Yamauchi, Ogasawara, & Nagai, 1992; Kido, 
Okumura, Yamada, Le, & Yano, 2007; LeBouder et al., 2008).  Besides the HA activators from 
animals, proteases in human airways includes TMPRSS2 (transmembrane protease, serine 2, also 
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known as epitheliasin) and HAT (human airway trypsin-like protease) that are capable of HA 
cleavage at a single arginine site (Bottcher et al., 2006). Due to the characteristics of these 
proteases, virus replication is restricted to the respiratory tract in the mammalian host, where these 
proteases are located. Some of the highly pathogenic avian influenza (HPAI) viruses have multiple 
basic cleavage sites that could be cleaved by ubiquitously expressed subtilisin-like proteases 
including furin and PC6. This adaptation change increased the pathogenicity of HPA1 viruses 
significantly, allowing them to spread systematically in susceptible poultry and humans, and even 
jump from poultries to mammalian hosts (Horimoto & Kawaoka, 2001).   
HA1 is the antigenic region of HA and is highly susceptible to develop mutations under 
the selection pressure of pre-existing antibodies. However, the receptor binding site (RBS) located 
on HA1 is highly conserved among different strains of influenza A viruses.  HA RBS consists of 
four loops named after their position on the amino acid sequence: 130-loop, 150-loop, 190-helix, 
and 220-loop. Besides the RBS, the HA stem region, which is primarily the HA2 region with a 
small part of the C-terminus of HA1, is also conserved among influenza strains (N. C. Wu & 
Wilson, 2017). 
 
Figure 1.4 The 3D structure of influenza HA. 
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The trimeric structure of influenza Globular head region (red) and stem region (green). Structure 
was derived from the HA sequence of A/Alberta/01/2014 (H5N1) virus by SWISS Model and was 
plotted by PyMOL software.  
 
There are five major antigenic sites in the globular head for H1 HAs: Sa, Sb, Ca1, Ca2, and 
Cb, and these antigenic sites are all surrounded by the sialic acid binding sites. The locations of 
Sa, Sb are on the distal tip of each HA monomer, while the remaining three antigenic sites are 
located near the stalk region (Xu, McBride, Nycholat, Paulson, & Wilson, 2012) (Figure 1.5). The 
five major antigenic sites have been discovered and mapped by locating the mutations on HA of 
the mutant virus that can escape the neutralization by a monoclonal anti-HA antibody. The 
antigenic sites on A/Puerto Rico/8/34 (PR8) virus were mapped with 34 antigenically unique PR8 
mutant viruses, 58 monoclonal anti-HA antibodies, and the resolved crystal structure of H3 HA as 
a reference (Gerhard, Yewdell, Frankel, & Webster, 1981). These five regions have been 
designated as antigenic sites of HA because epitopes on the monoclonal antibodies elicited by full-
length HA antigen were mostly mapped to those regions. Besides, these regions also fulfill the 
definition of discrete antigenic sites as any antibody binding to one site is not affected by the 











Figure 1.5 Major antigenic sites on H1 HA. 
The front and top view of the location of major antigenic sites Sa, Sb, Ca1, Ca2, and Cb on HA of 
H1 influenza viruses. The trimeric HA structure model is based on the HA of A/California/04/2009 
virus. The location of each antigenic sites is color-coded: Sa, red; Sb, blue; Ca1, green; Ca2, yellow; 
and Cb, purple. 
 
 
Antigenic site Sa and Sb are slightly overlapping in a spatial arrangement on the HA 
globular head; thus, they cannot be associated with antibodies simultaneously. The site Sa extends 
down along the  sheet structure on the opposite side of the HA to the RBD, while the site Sb 
occupies the region beside Sa in close proximity to the RBD. Site Sa includes residues 128, 129, 
158, 160, and 162 to 167 (excluding residue 164), while site Sb comprises residues 156, 159, 192, 
193, 196, and 198. Subsites Ca1 and Ca2 are located on the opposite side of the HA monomer. 
Subsite Ca1 contains residues 169, 173, 207 and 240, and the other subsite, Ca2, includes residues 
140, 143, 145, 224, and 225. Cb as a region near the bottom of the HA globular head is comprised 
of residues 78 to 83 (excluding residue 80) and residue 122 (Caton et al., 1982).  
The induction of different types of monoclonal antibodies targeting different antigenic sites 
on HA varies between influenza subtypes and host species (Matsuzaki et al., 2014; W. Sun et al., 
2019). The HA inhibition active monoclonal antibody of the antiserum obtained from H1 
influenza-infected mice is targeting Sb and Ca2 region of the HA. However, HA inhibition active 
antibody of infected ferrets is predominantly towards site Sa. In the adult human, the antibody 
pattern is yet different from in mice and ferret, the HA inhibition activity is significantly affected 
by site Sb and Sa on the antibody. The association of HA inhibition activity of the antigenic sites 
targeted by monoclonal antibodies has been defined to guide vaccine development (S. T. H. Liu et 
al., 2018). 
 
1.2.2 HA glycosylation 
To ensure the efficiency of the subunit influenza vaccine, it is critical to obtain functional 
viral antigens. Posttranslational modifications regulate functions of proteins by modulating their 
synthesize process. Among post-translational modifications, glycosylation is considered as one of 
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the most common and important modifications during protein synthesis (Jayaprakash & Surolia, 
2017; Moremen, Tiemeyer, & Nairn, 2012). Glycosylation plays a significant role in protein 
conformation, secretion, stability, solubility, and antigenicity (Mimura et al., 2018; Ryan & Cobb, 
2012; Scott & Panin, 2014). Although glycosylation seems to have profound effects on protein 
characteristics, it is controversial how glycosylation of HA in a subunit influenza vaccine would 
affect vaccine immunogenicity. On the one hand, glycosylation facilitates HA maturation and 
trimerization (Tate et al., 2014). Non-glycosylated HA antigen induced significantly lower virus-
specific antibodies in vivo comparing to the N-glycosylated HA immunogen, indicating 
glycosylation plays a crucial role in the immunogenicity of HA-based vaccine (Hutter et al., 2013). 
Furthermore, high titres of neutralizing antibody and superior protection activity were observed 
after immunization with HA antigens expressed in yeast, insect and mammalian cells, which 
proved that the glycosylated viral HAs could be high efficacious immunogens (Hu et al., 2019; 
Kopera et al., 2019; Y. Wang, Zhang, et al., 2017).  
 On the other hand, antibodies induced by HA antigen with only a single N-linked glycan 
at each glycosylation site had better receptor binding affinity and greater neutralizing ability 
comparing to antibodies raised against fully glycosylated HA protein (C. C. Wang et al., 2009). 
Moreover, HA antigens produced in a bacterial system (E. coli) that are commonly believed to 
have no glycosylation, were proved to be strongly immunogenic and used as promising candidates 
for supplying vaccine stocks against newly emerging influenza viruses, especially pandemics. HA 
antigen of A/H1N1/2009 virus produced in E.coli appeared to be correctly folded and exerted 
protective activity against the homologous virus challenge in the ferret model (Aguilar-Yanez et 
al., 2010). 
1.2.3 Current HA expression strategies 
A recombinant HA (rHA) vaccine as a promising subunit vaccine candidate could largely 
shorten the vaccine manufacturing time comparing to the egg-based approach. It requires lower 
standards of facility infrastructure during vaccine production. Particularly in the production of 
HPAI vaccine, the rHA strategy avoids the requirement for level 3 facilities and equipment. rHA 
proteins have mainly been produced in three expression systems: bacterial cells, insect cells and 
mammalian cells.  
Currently, HA1 subunit, HA2 subunit, and HA ectodomain have all been expressed in 
bacterial cells (Bommakanti et al., 2010; Farsad, Malekzadeh-Shafaroudi, Moshtaghi, Fotouhi, & 
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Zibaee, 2016; Saczynska et al., 2017). Relatively short production time and low maintenance cost 
have made bacteria-produced antigens a novel competitive way for vaccine production, while the 
potential concerns of antigens produced in prokaryotic cells are the proper folding and the 
glycosylation of antigens. HA1 of 2009 pandemic H1N1 produced in bacterial cells fused with 
bacterial flagellin (a TLR5 ligand) elicited robust neutralizing antibodies response and protected  
mice from a lethal challenge with homologous virus (Liu et al., 2011). Similarly,  recombinant 
flagellin-HA1 vaccine of H5N1(A/Vietnam/1203/04) induced high levels of HA-specific antibody 
and reduced nasal virus shedding in ferrets, and this flagellin-HA1 vaccination protected mice and 
ferrets against homologous viral infection (Liu et al., 2012; Song et al., 2009). Besides the HA1 
subunit vaccine, bacterially expressed HA ectodomain of H1N1 (A/California/07/2009) 
significantly reduced viral loads in the upper respiratory tract after homologous viral challenge in 
the ferret (Khurana et al., 2010). Recombinant HA0 of H5N1 (A/Vietnam/1203/2004) virus 
expressed in E.coli elicited high levels of HA-specific IgG after three injections of 15 g rHA 
antigen (Biesova et al., 2009) in mice.  
Moreover, recombinant proteins produced in mammalian cells acquired similar 
posttranscriptional modifications to that generated in the egg-based production system, which 
results in generation of fully glycosylated proteins. Various research has reported that eukaryotic 
HA head or ectodomain induced robust antigen- specific immune responses and provided superior 
protection rates against viral challenges (H. Lu et al., 2011; Pua et al., 2017).  HA1 of H5N1 
(A/Anhui/1/2005) virus fused with Fc fragment induced high neutralizing antibody titres against 
heterologous H5N1 strains and provided complete protection against lethal dose of heterologous 
H5N1 challenges in mice (Du et al., 2011). Immunization with HA ectodomain of H5N1 virus 
produced in a mammalian system  (A/Thailand/KAN-1/2004) with Ribi adjuvant in mice induced 
similar levels of serum IgG antibodies to that generated with inactivated influenza H5N1 
inactivated split vaccine (Wei et al., 2008). HA0 and HA1 proteins of H5N1 (A/Vietnam/1203/04) 
were produced in 293 Flp-In cell lines and were able to elicit homologous and heterologous H5N1 
neutralizing antibodies in rabbits (H. Lu et al., 2011). The overall manufacturing time of a rHA 
antigens from cloning, transfection, stable cell line generation and protein purification could be 
accomplished within 5-6 weeks, suggesting that mammalian rHA vaccines have the potential to 
become a modern approach to pandemic influenza outbreaks (H. Lu et al., 2011).  
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Similar to the mammalian expression system, antigens produced in insect cells are scalable, 
reproducible and were minimum endotoxin level, and the manufacturing process does not require 
high-levels of bio-containment facilities (M. M. Cox & Hollister, 2009). Vaccine antigens 
produced in insect cells also have posttranslational modifications, which may contribute to a better 
antigenicity of the protein. However, the HA antigen alone have a relatively low immunogenicity 
as a vaccine candidate and may require a prime-boost process or additional adjuvants to achieve 
protective immunity. FluBlok as the first non-egg-based vaccine licensed by World Health 
Organization (WHO) is produced in a baculovirus-based insect cell expression system (M. M. Cox 
& Hollister, 2009). Clinical data of FluBlok showed a stronger protection against influenza 
infection, especially in people with relatively weak immune responses. Besides the efficient 
commercialized recombinant subunit influenza vaccine, a study also proposed that a baculovirus-
based vaccine containing the rHA of the highly pathogenic H7N9 strain 
(A/Chicken/Jiaxing/148/2014) significantly reduced viral shedding and viral replication in 
vaccinated chickens compared to the inactivated whole virus of the same strain; the rHA antigen 
also fully protected immunized chickens from homologous virus challenge (Hu et al., 2019).  
 
1.3 Overview of influenza vaccines  
It has been 100 years since the first pandemic of influenza happened in 1918. Due to the 
constant mutation of the virus, it is impossible to eliminate the disease completely. Currently, the 
best intervention is to prevent the infection and spread of the virus by vaccination. The first 
influenza vaccine has been developed in the Soviet Union in 1936 attempting to vaccinate with a 
live-attenuated influenza virus. This vaccine has been produced by continuous passage  of the virus 
in eggs for over 30 times; as a result, the virus is only capable of causing mild infection, and the 
vaccinated subjects were protected from the reinfection of the same virus (Hannoun, 2013). Ever 
since then, the live-attenuated vaccines have been used for over 50 years in the Soviet Union. In 
the meantime, the inactivated virus vaccines have been developed in England and in the USA. For 
the development of inactivated virus vaccines, a large quantity of viral antigen is obtained from 
the virus propagated in allantoic fluid followed by formalin inactivation. All influenza vaccines 
were produced in an egg-based manufacturing system until 2012, when the cell-based vaccine 
Flucelvax® was approved by the US Food and Drug Administration (FDA) (Harding & Heaton, 
2018). Live attenuated vaccines use reassortment techniques to produce recombinant viruses with 
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six segments from a well-adapted PR8 virus with high growth rate and the HA and NA segments 
from the circulating viruses. These recombinant viruses possess a high yield property to facilitate 
the mass production and bear the antigenic property targeting the circulating viruses (Wong & 
Webby, 2013). 
Although the influenza vaccines are provided annually to the public, the variation of the 
effectiveness of the vaccines is attributed to two main reasons: the characteristic of the recipient 
(age, health conditions) and the matching of the vaccinated strains to the circulating strains. The 
overall effectiveness of the influenza vaccines, judging by the risk of influenza illness reduced by 
vaccines, is between 40% to 60% when the circulating viruses are well-matched to the vaccinated 
ones (CDC, 2019d). However, influenza vaccines may have reduced effectiveness in immune-
naïve young children or the elderly with decreased immune functions.  
To minimize the mismatches between the vaccine viruses and the circulating viruses and 
to improve the efficacy of seasonal vaccines, the WHO established a surveillance system to 
monitor the circulating influenza strains worldwide in several countries in 1952. This system 
allows the detailed analysis of influenza A (H3N2 and H1N1) viruses and influenza B viruses 
circulating in human or animal species, particularly in birds and pigs, which could facilitate the 
cross-species viral transmission.  Upon the discovery of new viral strains, the WHO will evaluate 
the antigenicity and the epidemiological behavior of the viruses, followed by the analysis of the 
viral sequences. The surveillance data are reviewed by the WHO investigators twice a year to 
determine which strains would possibly be circulating in the next flu season. Based on these 
reviews, the experts in WHO will decide which strains would be the best match and would be 
incorporated in this year’s seasonal flu vaccine (Gerdil, 2003).  
1.3.1 Types of influenza vaccines and commercial production 
The ultimate goal of influenza vaccines is to protect individuals from influenza infection 
and to provide an overall immunity to limit virus spreading within the population. There are three 
commonly used vaccines for influenza virus: the inactivated vaccine, the live attenuated vaccine 
and the recombinant subunit vaccine. Current seasonal vaccines on the market are mainly 
inactivated vaccines and live attenuated vaccines.   
1.3.1.1 Inactivated influenza vaccine (IIV) 
There are three main types of inactivated influenza vaccine: whole inactivated virus 
vaccine, split virus vaccine and inactivated subunit vaccine.  
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In whole inactivated virus (WIV) vaccine, the virus-containing fluid is chemically 
inactivated by formaldehyde or β-propiolactone, whereas in split virus vaccine, the virus is split 
by reagent such as ether, de-oxy-cholate, and detergents, such as Triton X-100 (Kon et al., 2016). 
In WIV vaccines and split virus vaccines, the chemical inactivators or splitting reagents are 
removed before sterile filtration and formulation. For inactivated subunit vaccines, the production 
also starts with the amplification of influenza viruses in embryonated eggs, followed by the 
inactivation of the virus and the stripping of the HA and NA protein from the lipid membrane by 
non-ionic detergents like Triton N101. After stripping, HA and NA could be efficiently separated 
from the viral core by density gradient centrifugation (Brady & Furminger, 1976). This additional 
purification step is required during the production of the subunit vaccine to remove the components 
necessary for viral replication, while the viral glycoproteins, which act as the major immunogens, 
would be purified out. Because of this purification step, a subunit vaccine contains no internal viral 
protein in contrast to WIV and split virus vaccine, which makes the inactivated subunit vaccines 
less reactogenic than the two inactivated vaccines (Talbot et al., 2015). Among the three types of 
inactivated vaccines, considering immunogenicity and adverse effects of the vaccines, and 
complicity of the vaccine production procedures, split virus vaccine is superior to the others. Thus, 
split virus vaccines have commonly been used as seasonal influenza vaccines.  
The adverse events of vaccines may affect a considerable number of recipients since 
vaccine coverage in many countries is increasing rapidly. Although the WIV vaccines are capable 
of inducing a robust immune response, they are also very reactogenic, which results in mainly 
local injection site infection and febrile illness (Tong et al., 2013). Thus, WIV vaccine now is 
mostly replaced by split virus vaccine; the disruption of influenza virions significantly reduces the 
adverse reactions in the recipients and increases the safety of the flu vaccine.  However, mild local 
reactions, including pain and redness in the injection site, are still associated with split virus 
vaccine, and they occur in over 25% of the elderly recipients and approximately 50% of the healthy 
adults (R. J. Cox, Brokstad, & Ogra, 2004).  
 The most widely applied seasonal influenza vaccine is the split virus vaccine in 
quadrivalent form, which is composed of 4 influenza strains that are predicted to be circulating in 
the upcoming flu season. Quadrivalent inactivated vaccine was licensed in 2012 and contains four 
types of virus strains: two influenza A strains (H1N1 and H3N2) and one or two influenza B types 
(Yamagata and Victoria). These vaccines are standardized by the quantity of hemagglutinin 
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contained in the vaccine. The initial splitting reagent is ether; however, ether is reported to have 
local toxicity (skin or eyes irritation) and to interfere with the HA quantification procedure. 
Consequently, ether is replaced by other splitting reagents in commercial vaccine production, such 
as de-oxy-cholate (Afluria, Fluarix, and Flulaval) and TritonX-100 (Fluarix, Flucelvax, 
and Fluzone) (Prevention, 2015).  For adults, there are commonly 15 µg of HA per strain in 
seasonal flu vaccines; whereas for the elderly, higher doses (60 µg of HA per strains) of vaccines 
are licensed (DiazGranados et al., 2014). Inactivated vaccines have an excellent safety record, and 
it is recommended to a broad range of recipients. Different inactivated vaccines are approved to 
apply to different age groups because certain age groups are at high risk of developing severe 
complications from influenza infection. Children aged 6 month to 8 years who have never been 
vaccinated before or people aged 65 years and older, due to their weak self-immunity, requires 
high doses of vaccines or adjuvanted vaccines that could provide stronger immune responses 
following vaccination (CDC, 2019b, 2019c). The most frequently used quadrivalent inactivated 
vaccine Fluzone® (Sanofi Pasteur) is applied to children older than six months of age, the elderly, 
pregnant women, and people with chronic health conditions.  
IIV vaccines are capable of inducing serum antiviral responses, which is predominantly the 
increase of serum IgG levels. The serum IgG level is detected by enzyme-linked immunosorbent 
assay (ELISA), and viral-specific neutralizing antibody in the serum is identified by the 
hemmaglutination inhibition (HI) assay. The serum antibody appears to be effective in neutralizing 
the upcoming viruses in the infection site, which is on the mucosal layer of the respiratory tract 
(Wagner et al., 1987).  
1.3.1.2 Live attenuated influenza vaccine (LAIV) 
Although LAIV has been used in the early 1930s in the Soviet Union, the vaccine was 
licensed in the US in 2003 for 2 - 49 years old recipients, and not until 2012 the vaccines were 
recommended to be used in Europe for children aged 2 -17 years (R. J. Cox, 2013; Sridhar, 
Brokstad, & Cox, 2015). The development of LAIV is based on HA and NA from the specific 
virus strains predicted by WHO to be circulating in the next flu season and the backbone from an 
attenuated, cold-adapted virus. There are two different cold-adapted virus development 
technologies: First, the backbones used in Russia (Ultravac) and India (Nasovac-S) are 
A/Leningrad/134/17/57 (H5N2) and B/USSR/60/69 for influenza A and B viruses, respectively 
(Rudenko, Yeolekar, Kiseleva, & Isakova-Sivak, 2016). Second, Ann Arbor backbone produced 
20 
 
by AstraZeneca in the UK by serial passaging the WT A/Ann Arbor/6/60 strain in primary chicken 
kidney cells at successively low temperature (Maassab, 1967). LAIV using the Ann Arbor 
backbone is commercialized in North America and Europe under the names FluMist and 
Fluenz, respectively.   
The master donor virus, which provides the six internal gene segments except HA and NA 
segments, in LAIV is temperature sensitive.  This virus could only replicate at 33C, but its growth 
is restricted in temperature condition above 37.8C; therefore, the replication of the attenuated 
virus incorporated in the vaccine is restricted to the human upper respiratory tract and does not 
replicate in lower respiratory tracts, where the temperature condition is over 37.8C (Trombetta, 
Gianchecchi, & Montomoli, 2018). For this reason, there is less chance to develop severe influenza 
infections after immunization with LAIV. The master donor virus has a significantly low reversion 
rate after multiple passages in infected hamsters (Jin et al., 2003). The of LAIV is more efficacious 
than IIV vaccine, with 80% protection in children aged younger than six years old and 40% 
efficacy in adults (Sridhar et al., 2015).  
LAIV is administrated intranasally (needle-free), and it elicits a longer-lasting and broader 
immune responses (humoral and cellular). Comparing to the conventional intramuscular delivery 
of seasonal influenza vaccines, the administration method of LAIV not only largely benefits young 
children with possible fear of needles, but also closely resembles the natural infection scenario of 
influenza virus. The LAIV immunization is capable of inducing various adaptive immune 
responses including high levels of serum antibody, strong mucosal responses, and cytotoxic T cells 
targeting influenza virus (Isakova-Sivak & Rudenko, 2015).  
 In comparison to IIV-induced serum IgG responses, LAIV immunization mainly elevates 
local immune responses associated with the secretion of antiviral IgA antibody. Virus-specific IgA 
is believed to protect the mucosal surface against viral infection by neutralizing the upcoming 
viruses or preventing viral attachment to the mucosal epithelium. Although plasma antibody is 
capable of preventing viral infection in lower respiratory organs, such as lung, it is not proved to 
be effective in protecting mice and ferrets from upper respiratory tract viral infection.  In terms of 
disease transmission, mucosal IgA antibodies, but not plasma IgG antibodies, are more efficient 
in reducing viral shedding in nasal secretions after influenza infection (Renegar, Small, Boykins, 
& Wright, 2004).   
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However, LAIV has been reported to cause slightly more adverse reactions compared to 
IIV. Thus, LAIV is not recommended to young children under 2 years of age, the elderly, and the 
immunosuppressed people. Besides, an increased risk of asthma is reported to be associated with 
LAIV immunization in young children prone to develop asthma; thus, LAIV should not be 
administrated to any individual with asthma or children under 5 years of age with recurrent 
wheezing (Bergen et al., 2004; Kelso, 2012). Upon LAIV immunization, viruses could be isolated 
from nasal swabs in young children until seven days post-immunization, but it is undetectable over 
14 days post-vaccination (R. Belshe, Lee, Walker, Stoddard, & Mendelman, 2004). The adverse 
effects associated with LAIV are not severe; these include running nose and sore throat on the day 
of immunization, and slight fever on 2 to 9 days post-vaccination. Moreover, research showed that 
the LAIV exerted lower effectiveness against H1N1 virus in some studies over several flu seasons 
since 2013 in the USA. Due to these adverse effects and inconsistent vaccine efficacy in the USA 
and Europe, the use of LAIV was not recommended for the 2016-2017 and 2017-2018 flu seasons 
in the US. The recommended use of LAIV was resumed for the 2018-2019 flu season (Caspard et 
al., 2016; CDC, 2019a; Trombetta et al., 2018).  
In the case of seasonal influenza vaccines, IIV has been administrated annually as the 
injectable vaccine and LAIV has been recommended as the nasal spray on and off in the market. 
However, both IIV and LAIV are based on the egg-based manufacturing system, which takes up 
to 6 months to produce the vaccines. Upon emerging influenza virus explosions, egg-based 
manufacturing system would need a response time of several months, which would create a gap in 
the immunogenically naïve population and allow the spread of the emerging viruses. Thus, there 
is a need to generate influenza vaccines in a short amount of the time to respond to the antigenically 
distinct influenza virus explosions.  
1.3.1.3 Recombinant subunit influenza vaccine 
The majority of commercial influenza seasonal vaccines are inactivated or live-attenuated 
vaccines, but there are a few recombinant subunit influenza vaccines in the market. Recombinant 
subunit influenza vaccine contains purified viral glycoprotein HA or NA from recombinant protein 
expression systems. Recombinant proteins are expressed and purified from various systems 
including mammalian cells, insect cells, bacteria, and yeast; thus, the production of recombinant 
flu vaccine does not require chicken eggs (Gadalla, El-Deeb, Emara, & Hussein, 2014; Lei, Jin, 
Karlsson, Schultz-Cherry, & Ye, 2016; H. Lu et al., 2011). There are several advantages of 
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recombinant subunit vaccines over the current seasonal vaccines produced in embryonated eggs. 
Firstly, the recombinant proteins are produced in a scalable and reproducible process in various 
types of cells. Secondly, the manufacturing process is more rapid and costly effective than the 
conventional egg-based system, in the event of the emerging pandemic strains. Thirdly, 
recombinant subunit vaccine avoids the adaptation step required in the egg-based vaccine 
production system. This additional viral adaptation step in eggs is aim to acquire high levels of 
recombinant virus, which does not commonly replicate in avian species, for vaccines manufacture. 
Fourthly, the production of recombinant proteins does not require chemical inactivation or organic 
extraction procedures, which reduces the chance of residual toxicity in the vaccine (M. M. Cox, 
Patriarca, & Treanor, 2008).   
 FluBlok is a recombinant HA vaccine developed by Protein Sciences Corporation. This 
rHA vaccine is a trivalent vaccine formulated with HA antigens from three influenza strains 
comprised of two influenza A viruses and one influenza B virus, which are selected to be included 
in the annual flu vaccine by the WHO around February every year. The three HA proteins 
incorporated in the recombinant subunit vaccine are produced in a continuous insect cell line 
derived from Sf9 cells of fall armyworm using baculovirus as vectors. After the expression, HA 
antigens are purified from serum-free media by column chromatography. The HA antigens in the 
FluBlok vaccine are full-length HA proteins containing both HA1 and HA2 regions. FluBlok 
contains 45 g HA of each virus, which is three times the amount of antigen incorporated in a 
common inactivated influenza vaccine (M. M. Cox et al., 2008). Clinical data proved that 
FluBlok provided stronger protection against influenza infection in the elderly and immuno-
compromised people comparing to the inactivated influenza vaccine. Meanwhile, FluBlok also 
induced an enhanced antibody response towards the influenza virus, which is comparable to that 
induced by IIV, in healthy adults. However, the increased amount of antigen in FluBlok may also 
associate with a higher rate of local injection site pain, headache, muscle pain and fatigue (W. A. 
Keitel et al., 1996). Thus, FluBlok vaccines are licensed by the FDA to be used in adults over 18 
years old.  
Despite the advantages in recombinant subunit vaccine production, drawbacks of the 
vaccine manufacture process remain. Comparing to the egg-based vaccine manufacture system 
that was established over 50 years, large-scale infrastructure for recombinant subunit vaccine 
production does not exist worldwide. Moreover, the subunit vaccine has relatively low 
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immunogenicity compared to conventional vaccines; therefore, prime-boost strategy and the use 
of adjuvants are necessary steps to improve the efficacy of recombinant subunit vaccines.  
1.3.2 Universal vaccines 
Although current influenza vaccines are efficacious and are the best countermeasures to 
influenza infection, the decline of existing neutralizing antibodies and the constant mutations in 
influenza viruses necessitates the annual updates of the seasonal influenza vaccines. Current 
influenza vaccines induce neutralizing antibodies towards the main antigen of influenza HA, which 
changes continuously due to the error-prone viral polymerases and the selection pressure posed by 
pre-existing antibody in the human population (human herd immunity). The development of a 
universal vaccine, which covers broader ranges of influenza strains, provides long-lasting 
protection and avoids the needs for annual vaccination. In the universal influenza vaccine strategic 
plan of the National Institute of Allergy and Infectious Diseases, they stated that a universal flu 
vaccine should provide protection against both group I and II influenza A viruses, and the vaccine 
needs to provide protection that lasts at least one year in all age groups (Coughlan & Palese, 2018).  
To design a universal influenza vaccine providing broad cross-reactive immunity, the 
conservative proteins or domains of influenza virus are the promising candidates for vaccine 
development. Several approaches to develop universal influenza vaccines focused on the 
conserved region of HA protein, glycoprotein NA, the ectodomain of ion channel protein M2, and 
the combination of nucleoprotein NP and matrix protein M1 (Estrada & Schultz-Cherry, 2019; 
Nachbagauer & Krammer, 2017). There are three strategies to develop universal vaccines inducing 
immune responses against the conservated stem region of HA protein: the production of headless 
HA stem immunogens, immunization with chimeric HA viruses, and sequential immunization 
with the combination of live-attenuated vaccine and inactivated vaccine.  
The reason for generating headless HA stem immunogens is that the stem region of HA is 
highly conserved among different influenza strains, which makes it an ideal candidate to induce 
broadly protective immune responses (Figure 1.4). However, HA stem in neutral pH is not exposed 
to the viral surface due to the steric hindrance of the HA head, which is an immunodominant region 
on HA. Thus, it is difficult to mount immune responses against HA stem region in a natural 
infection, and this necessitates the expression of HA stem alone in vitro. Stable mini-HA stem 
antigen based on HA from H1N1 (A/Brisbane/59/2007) derived from a mammalian system was 
capable of forming intermolecular trimers and binding to the known broadly neutralizing 
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antibodies, which confirms the proper folding of the protein. This mini-HA immunogen also 
completely protected mice from lethal challenge with heterologous and heterosubtypic viruses. 
Moreover, mini-HA stem immunogen expressed in a mammalian system significantly reduced 
fever after heterologous viral challenge in cynomolgus monkeys and reached a comparable effect 
compared to vaccination with trivalent seasonal influenza vaccine (Impagliazzo et al., 2015). 
However, there are some limitations of stem-based immunogens. The mini-HA stem immunogen 
has been reported to be effective for the group I influenza virus, but not group II or influenza B 
viruses (Krammer, 2015).  Besides the relatively narrow protection ranges, antibodies induced by 
mini-HA stem might promote virus fusion, facilitate the intake of the virus, and enhance virus-
associated respiratory disease (Khurana et al., 2013).   
In the chimeric HA virus immunization strategy, viruses with chimeric HAs, consisting of 
the stem region of the same virus and the head domain of various heterologous or heterosubtypic 
viruses within the group I influenza A virus, are generated (Isakova-Sivak et al., 2018; T. T. Wang 
et al., 2010) (Figure 1.5). Repeated immunization  with viruses containing chimeric HAs that 
express the same HA stem could induce enhanced immune responses against the stem region 
(Nachbagauer et al., 2017). In this study, mice were electroporated with a DNA vaccine encoding 
cH9/1 (HA head from an H9 isolate and stem from H1N1 virus) and were boosted with a 
baculovirus expressed cH6/1 (H6 head and H1 stem) protein followed by a repeated boost of 
baculovirus expressed cH5/1 (H5 head and H1 stem) protein. Immunization with the sequential 
chimeric HA vaccines protected mice from heterologous and heterosubtypic influenza viral 
challenges, suggesting that chimeric HA vaccination elicited broad immune responses against 
group I influenza viruses. However, chimeric HA vaccines could not protect mice from challenge 
with the H3N2 virus, which is an HA group II virus, suggesting that the chimeric HA failed to 
provide intergroup protection against influenza viruses (Krammer, Pica, Hai, Margine, & Palese, 
2013).  
Another strategy to develop immune responses towards conserved epitopes on HA is 
through a sequential immunization regime (Zhou et al., 2017). Researchers proved that initial 
immunization with LAIV vaccine, which significantly resembles the natural influenza infection, 
along with a boost with subunit vaccine would elicit a protective stem-derived antibody response 
(Nachbagauer et al., 2017). Moreover, ferrets vaccinated with LAIV vaccine expressing cH8/1 
(H8 head and H1 stem), followed by a boost of inactivated whole virus vaccine of cH5/1 (H5 head 
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and H1 stem) developed reduced viral titres in the upper respiratory tract after H1N1 viral 
challenge, suggesting that the combination of prime-boost and chimeric HA strategy generated 
superior protection against heterologous viral challenges (Nachbagauer, Krammer, & Albrecht, 
2018). One advantage of this strategy is that previous natural influenza infections in the host, which 
served as prime vaccinations, already induced some baseline stem-directed antibodies; thus, a 
prime vaccination might not be required within this strategy (Margine et al., 2013).  
1.3.3 H5N1 vaccines 
Since the first human infection case of avian influenza H5N1 virus reported in 1997 in 
Hong Kong, the avian-origin H5N1 virus has rapidly developed into various subclades and spread 
to more than 16 countries during 2003 to 2019 with over 50% motility rate in humans (Subbarao 
et al., 1998; WHO, 2019b). There has been a global effort since 2005 to develop vaccines against 
the avian-origin H5N1 virus and other influenza viruses of pandemic potential (K. R. Talaat et al., 
2014).  Both conventional and novel strategies have been used to develop effective anti-H5 
influenza vaccines. There are 21 licensed human anti-H5 pre-pandemic vaccines available in the 
market until 2013; most of them are inactivated virus vaccine, and one of them is a live-attenuated 
vaccine (WHO, 2013).  
Aside from the licensed H5 vaccines, many new pre-pandemic H5 vaccines are under 
development. Research showed that LAIVs might be more beneficial in providing protection 
against influenza pandemics due to their high replication efficiency and yield in eggs and their 
rapid induction of antiviral responses (Manuell, Co, & Ellison, 2011). One study on the production 
of the LAIV H5N1 vaccine showed that the cold-adapted H5N1 (A/Vietnam/1203/2004 and 
A/Hong Kong/213/2003) vaccines bearing avian H5 HA antigens were significantly attenuated 
and able to induce serum antigen-specific antibodies and neutralizing antibodies in healthy adults 
(Karron et al., 2009). Moreover, another study on LAIV H5N1 vaccine also stated that cold-
adapted influenza vaccine with HA and NA from another H5N1 virus (A/Anhui/2/2005) could 
provide protective immunity against the highly pathogenic H5N1 challenge in a nonhuman primate 
model (Fan et al., 2009).  
Other studies on inactivated H5N1 vaccines showed that adjuvanted H5N1 inactivated 
vaccine (Sanofi) based on A/Vietnam/1203/2004 induced high levels of HA-specific IgG, but 
relatively low levels of serum neutralizing antibodies (Wong et al., 2017). A clinical study also 
demonstrated that an inactivated whole-virion vaccine derived from A/Chicken/Astana/6/05 of 
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H5N1 virus formulated with the aluminum hydroxide adjuvant was safe and well tolerated in the 
immunized individual, and a single immunization of adults with this inactivated vaccine appeared 
to be immunogenic (Sansyzbay et al., 2013).  
New vaccine technologies, which utilize non-egg-based production methods, intended to 
rely on the production of recombinant HA of the avian H5N1 virus are being developed. Clinical 
data suggested that MF59-adjuvanted, cell culture-derived, subunit H5N1 vaccine with 7.5 µg of 
HA antigen derived from A/turkey/Turkey/1/05 (H5N1)-like strain (NIBRG-23) was strongly 
immunogenic in healthy adults or elderly subjects in 2 phase II studies (Frey et al., 2019).  
These efforts in providing an economical, safe, inexpensive and effective pre-pandemic 
influenza vaccine will significantly broaden the scope of pandemic preparedness and create high-
performance vaccines.  
 
1.4 Common vaccine adjuvants 
An adjuvant is a component used in some vaccines that could enhance the immune 
response induced by antigens in vaccinated people; in other words, the adjuvants significantly 
increase the immunogenicity of the vaccine. Traditional adjuvants such as aluminum salts have 
been used in human vaccines since 1932, and aluminum salts was the only adjuvant approved to 
be used in licensed vaccines for over 70 years (Marrack, McKee, & Munks, 2009).  
Currently, the development of novel adjuvants for vaccine use is an area of high interest. 
Several factors need to be considered in the selecting of an ideal vaccine adjuvant, such as safety, 
tolerance, manufacturing process, shelf life, compatibility with viral antigen, and feasibility. 
Among these crucial factors, the benefit to risk ratio of adjuvants in specific vaccines is a 
prioritized criterion in adjuvants development (Brito, Malyala, & O'Hagan, 2013).  
1.4.1 Functions of adjuvants 
Several reasons are listed below for the use of adjuvants in vaccines.  
Firstly, an adjuvant serves as an additional component that boosts the immune response in 
specific recipients with low reactions to regular vaccinations. This recipient population includes 
immune-compromised patients, young children who are immunogenically naïve to viral infections, 
and the elderly suffering from reduced immune responses. Adjuvant System 03 (AS03) and MF59 
have been widely used as adjuvants in commercial influenza vaccines. AS03 adjuvant enhanced 
the antibody responses induced by the H1N1 2009 pandemic influenza vaccine (Arepanrix, GSK) 
27 
 
in patients with HIV infection (Yam et al., 2014). The MF59-adjuvanted trivalent subunit vaccine 
was more effective and induced higher antibody titres in children than the non-adjuvanted vaccine 
(Nolan et al., 2014).  
Secondly, besides boosting the relatively weak immune responses in specific hosts, 
adjuvants are also capable of improving the immunogenicity of weaker antigens that are naturally 
less immunogenic. The conventional egg-based influenza seasonal vaccines, including LAIV and 
IIV, are based on viral antigens derived from the whole virions; however, the new approaches of 
subunit vaccines development often utilize recombinant proteins as antigens. The possible reason 
that some subunit vaccines are less immunogenic than the whole virion-derived vaccines is that 
pathogen-derived vaccines have other viral proteins in addition to the highly purified viral 
glycoprotein (subunit vaccines), and these additional proteins could enhance the immune 
responses generated by a single viral antigen.  
Thirdly, adjuvants could efficiently reduce the frequency of vaccine administration and the 
doses of antigen incorporated in the vaccine. During pandemic influenza strikes, most vaccines 
need multiple administrations to reach ideal efficacy and provide protection to recipients. However, 
the addition of an efficacious adjuvant is capable of reaching the protectable threshold after only 
one vaccination. MF59-adjuvanted inactivated H9N2 virus induced similar levels of serum 
antibody to 2 doses of non-adjuvanted vaccine (Atmar et al., 2006).   
Fourthly, adjuvants could also change the types of immune responses induced by viral 
antigen via altering the secretion pattern of cytokines and chemokines, which leads to differences 
in recruiting immune cells. Particularly, T cell responses could be changed drastically by 
formulation of different adjuvants with the same antigen. HA antigen pairing with MF59 or Alum 
adjuvant induced higher levels of serum IgG1 antibody and increasing numbers of IL-5 secreting 
T cells, suggesting the activation of Th2 biased cellular response, whereas vaccination consisting 
of the same influenza antigen combined with the cationic liposomal adjuvant CAF01 generated a 
Th1 and Th17 biased subpopulation of T helper cells (Knudsen et al., 2016).  
Although adjuvants all have the ability to improve the efficacy of viral antigens by boosting 
the host immune system, the mechanism of individual adjuvant action is drastically different due 
to their diversified compositions. Some adjuvants could help soluble antigens to be retained at the 
injection site to prevent quick clearance of antigens by lymphatics. Insoluble adjuvants like Alum 
or oil-in-water emulsions including MF59, AS03, and AF03 could all lead to the retention of 
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antigens (Hutchison et al., 2012). MF59, AS03 could also elevate the local immune responses by 
increasing the recruitment of immune cells to the injection site either directly or indirectly through 
the release of cytokines and chemokines (Calabro et al., 2011; Morel et al., 2011). Moreover, 
adjuvants such as TLR agonists are able to stimulate the innate immune responses by activation of 
antigen-presenting cells; particularly pattern recognition receptors (PRR) (Choi et al., 2012; 
McCarron & Reen, 2009). PRRs, including toll-like receptors, rig-like receptors, and 
inflammasomes, are crucial in recognizing foreign antigens and inducing immune responses. 
Adjuvants trigger PRR recognition either directly by interactions or indirectly by inducing local 
damage that would be detected by inflammasomes (Tregoning, Russell, & Kinnear, 2018).  
1.4.2 Adjuvants in commercial influenza vaccines  
Many researchers have developed various adjuvant candidates that are capable of actively 
enhancing the immune responses induced by viral antigens, and a few of these discoveries have 
been commercialized and incorporated in licensed vaccines. There are three licensed adjuvants in 
the USA including aluminum salts, MF59, and AS03 (Shah, Hassett, & Brito, 2017). Each of the 
adjuvants have its advantages and disadvantages, and the study of current adjuvants provides 
valuable insights into the development of future adjuvants.  
Aluminum salts are the name for two different adjuvants: aluminum phosphate and 
aluminum hydroxide, which have different properties but the same product name in the vaccine 
community. Alum mainly functions as an antigen delivery system by associating with antigens 
through electrostatic interactions or ligand exchanges. The interaction of antigens and aluminum 
salts enables the retention of antigens at the injection sites for an extended period, which promotes 
the antigen uptake by antigen-presenting cells including monocytes and macrophages (Bastola et 
al., 2017). Besides that, the injection of alum adjuvants has been shown to stimulate immune 
responses by activating the NACHT, LRR and PYD domains-containing protein 3 (NLRP3) 
inflammasome and triggering PRRs (Awate, Babiuk, & Mutwiri, 2013; Tregoning et al., 2018).  
However, alum could not efficiently induce mucosal IgA antibodies, and adverse effects of alum 
adjuvants include the potential of granulomas, allergenicity, neurotoxicity induced by 
immunization. In addition, aluminum salts shift the immune response towards a Th2 biased 
phenotype, which leads to the secretion of IgE antibodies that possibly associate with allergic 
reactions in some research subjects (Petrovsky & Aguilar, 2004). Aluminum is the most widely 
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used adjuvant, and various researchers stated that the safety and potency profile of alum adjuvant 
might associate with the types of antigen co-formulated in the vaccine.  
MF59 is the second adjuvant approved for human use after aluminum salts, and it was first 
approved for human use in 1997 in Italy. Shortly after the first approval, MF59 has been used as a 
component for the influenza vaccine for seniors (Rambe, Del Giudice, Rossi, & Sanicas, 2015). 
MF59 is an oil-in-water emulsion and composed of squalene, Span 85, and Tween 80 in sodium 
citrate buffer. MF59 is also a potent adjuvant to compensate for the lower antigen concentration 
in vaccines (O'Hagan, Ott, Nest, Rappuoli, & Giudice, 2013). The mechanism of MF59 is that it 
does not create depot at the injection site but induces the influx of antigen-presenting cells at the 
site of injection either directly or indirectly by upregulating the production of cytokines and 
chemokines (O'Hagan, Ott, De Gregorio, & Seubert, 2012). The recruitment of antigen-presenting 
cells further leads to an increase in antigen uptake by neutrophils and monocytes and promotes the 
delivery and translocation of antigens to immune-competent cells (N. C. Wu & Wilson, 2017). 
Clinical trials with MF59-adjuvanted vaccines have been completed in different age groups with 
different types of antigens, and most of these MF59-adjuvanted vaccines proved to enhance the 
immunogenicity induced by co-vaccinated antigens with a high safety and tolerance profile. 
Particularly, in 2009, the safety profile of the seasonal flu vaccine Fluad in children has been 
identified with 89 subjects, indicating that the MF59-adjuvanted influenza vaccine is safe and 
highly immunogenic in young children (Vesikari, Groth, Karvonen, Borkowski, & Pellegrini, 
2009). However, granuloma formulation, injection site pain, and inflammatory reactions are the 
most common adverse effects of MF59-adjuvanted vaccine.  
AS03, developed by GlaxoSmithKline Biologicals (GSK; Rixensart, Belgium), is also an 
oil-in-water adjuvant, which is composed of squalene, DL-α-tocopherol and Tween80 in 
phosphate buffered saline. AS03 is required to co-localize with antigens at the injection site to 
generate an enhanced immune response, and it works similarly to MF59 and can induce an 
enhanced immune response with co-vaccinated antigens. The critical component in AS03 is DL-
α-tocopherol, an isoform of vitamin E, which is found to be antioxidant and immunogenic in 
human. The presence of DL-α-tocopherol can upregulate the expression of some proinflammatory 
cytokines and chemokines including Chemokine (C-C motif) ligand CCL2, CCL3, IL-6, and 
Chemokine (C-X-C motif) ligand CXCL1 (Morel et al., 2011). Moreover, AS03 induces the 
expression of transcription factor NF-κB and recruits innate immune cells, particularly monocytes 
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and granulocytes, to the site of vaccination. Specifically, monocytes recruited by AS03 at the 
injection site are then activated, converted to antigen-presenting cells, and migrated to draining 
lymph nodes. AS03 has been incorporated in the pandemic H1N1 2009 vaccine and induced 
increased levels of anti-influenza antibody comparing to nonadjuvanted H1N1 vaccines (Garcon, 
Vaughn, & Didierlaurent, 2012). AS03 as an emulsion similar to MF59 also has side effects like 
soreness at site of injection, granuloma formulation, and sometimes inflammatory reactions. 
1.4.3 Triple adjuvants 
Aside from the adjuvants used in commercial influenza vaccines, innate immune receptor 
ligands and host defense peptides can also be used individually as adjuvants in vaccine 
development, and a combination adjuvant consisting of these two adjuvants is also under 
development (Duthie, Windish, Fox, & Reed, 2011; Goff et al., 2015; Levast et al., 2014; Mendez-
Samperio, 2014; Polewicz et al., 2013). Vaccine and Infectious Disease Organization - 
International Vaccine Centre (VIDO-InterVac) patented triple adjuvant (TriAdj), which is 
comprised of three components: polyriboinosinic acid-polyribocytidylic acid (poly(I:C)), a Toll-
like receptor (TLR) agonist; Innate defense regulator (IDR)-1002, a host defense peptide; and 
polydi(p-oxyphenylpropionate) phosphazene (PCEP, polyphosphazene), a synthetic polymer 
(Garg, Latimer, Gerdts, Potter, & van Drunen Littel-van den Hurk, 2014; Mutwiri et al., 2007; 
Niyonsaba et al., 2013). Poly(I:C) as an adjuvant is used to mimic viral double-stranded RNAs 
and stimulate immune responses against intracellular pathogens. The signaling of Poly(I:C) 
adjuvant is dependent on TLR3 and melanoma differentiation-associated gene-5 (MDA-5), and 
Poly(I:C) can induce a cell-mediated immune response and type I interferon response (Hafner, 
Corthesy, & Merkle, 2013). The IDR-1002 could mediate immune responses through 
phosphoinositide 3-kinase (PI3K), nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-B), and mitogen-activated protein kinase (MAPK) pathways, and it is also associated with 
chemokine induction and the recruitment of monocytes and neutrophils to the injection site 
(Madera & Hancock, 2012; Nijnik et al., 2010). Another component of the TriAdj, PCEP, is able 
to induce an early innate immune response and trigger the production of pro-inflammatory 
cytokines and chemokines including CCL2 at the site of injection (Awate, Wilson, Lai, Babiuk, & 
Mutwiri, 2012).   
The TriAdj proved to be highly effective in combination with various human viral and 
bacterial antigens for infectious diseases in different animal models. TriAdj formulated with viral 
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antigen from the human respiratory syncytial virus (hRSV) induced a long-term immune response 
in mice by producing neutralizing antibodies, memory B cells and CD8+ T cells (Garg et al., 2014). 
Similarly, when co-formulated with Bordetella pertussis antigen, TriAdj induced a greater Th-1 
immune response with a significant increase in levels of IgG2a antibody in mice (Gracia et al., 
2011).  
The mechanisms of how the TriAdj works as a vaccine adjuvant were identified in previous 
studies. As a mucosal vaccine adjuvant, the TriAdj could increase the antigen uptake process by 
dendritic cells (DCs), accelerate DC maturation, and facilitate the antigen presenting process to T 
cells (Garg et al., 2014). In combination with RSV antigen, the TriAdj is able to induce the 
expression of pro-inflammatory cytokine and chemokines in both upper and lower respiratory 
tracts, and the upregulation later leads to the recruitment of DCs, macrophages, and neutrophils 
and provides a long-term protective immune response in mice (Sarkar, Garg, & van Drunen Littel-
van den Hurk, 2016).  
 The TriAdj as an adjuvant has the potential to stimulate tailored immune responses that is 
beneficial to specific viral or bacterial antigens co-formulated in the vaccine through the 
stimulation of multiple pathways and the induction of various immune cells.  
 
1.5 Objectives and Aims  
The HPAI H5N1 virus has a high potential to acquire inter-human transmission ability; 
along with its high mortality in the human population, the HPAI H5N1 virus is considered to be a 
candidate that could cause potential pandemics. However, the current vaccines stock against 
potential pandemic explosions are mostly inactivated vaccines and live attenuated vaccines, which 
all have relatively longer production time and higher production cost in comparison to the subunit 
vaccine. The novel subunit vaccine based on the production of recombinant antigenic protein is 
scalable, reproducible, timely, and cost effective in the case of a pandemic outbreak. Meanwhile, 
regarding the weak antigenicity of H5 HA antigens, adjuvants are essential elements to enhance 
antigenicity in subunit anti-H5 vaccines. Aside from the commercial adjuvants, the TriAdj has 
been shown to induce strong immune responses when formulated with various viral and bacterial 
antigens in multiple animal models. Thus, the overarching objective of my thesis project is to 
explore whether the recombinant subunit HA with TriAdj would be a promising vaccine to protect 
against H5N1 influenza infection.  
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I hypothesize that the H5 HA protein expressed in a mammalian system is glycosylated 
properly for its antigenicity compared to the HA protein expressed in a bacterial expression system. 
Furthermore, the TriAdj could enhance the H5 HA protein antigenicity, inducing better immune 
responses.  
I propose three specific aims to reach my overarching objective.  
Aim 1. Establishment of a mouse HPAI H5N1 virus model for evaluation of the 
potential vaccines. 
Aim 2. Design, expression and purification of the HA immunogens in both 
mammalian and bacterial expression systems. 
Aim 3. Characterization of HA immunogens in vitro and evaluation of the immune 
responses and protection efficacy of the HA immunogens in vivo 
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CHAPTER 2 ANIMAL MODEL ESTABLISHMENT FOR THE HPAI H5N1 VIRUS IN 
MICE 
 
The use of animal models in disease study is important. It allows us to precisely 
characterize viral replication and viral pathogenicity in vivo; it is also essential for developing 
countermeasures against the viral infections. To test a vaccine candidate against HPAI H5N1 virus, 
I needed to first establish the disease model in mice. While human HPAI H5N1 infections have 
typically been reported in Asian countries, Canada reported a case of fatal human infection by the 
HPAI H5N1 virus in 2014. The full-genome analysis of the causative virus A/Alberta/01/2014 
(H5N1) (AB14 (H5N1)) indicated that it showed over 99% identity with the avian originated 
H5N1 virus in nucleotide and protein levels in all its segments, except the PB2 segment. In addition 
to its high resemblance to the HPAI avian influenza virus, it caused a fatal infection in humans 
with unique neurological symptoms and encephalitis (Pabbaraju et al., 2014).  The human infection 
case indicated that the AB14 (H5N1) virus has inter-species transmission potential and is capable 
of inducing neurological disorders. When I started my project there was only genome analysis 
available for the AB14 (H5N1) virus; the pathogenesis and the mechanisms underlying the 
virulence of AB14 (H5N1) in vivo remained elusive.  
In this chapter, I investigated the pathogenicity as well as the cytokine and chemokine gene 
transcription profiles of the AB14 (H5N1) virus in mice and established a mouse model for this 
strain of the virus, which allows the evaluation of potential vaccines in vivo. This study is presented 
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Highly pathogenic avian influenza (HPAI) H5N1 and low pathogenic avian influenza 
(LPAI) H7N9 viruses pose a severe threat to public health through zoonotic infection, causing 
severe respiratory disease in humans. While HPAI H5N1 human infections have typically been 
reported in Asian countries, avian H7N9 human infections have been reported mainly in China. 
However, Canada reported a case of fatal human infection by the HPAI H5N1 virus in 2014, and 
two cases of human illness associated with avian H7N9 virus infection in 2015. While the genomes 
of the causative viruses A/Alberta/01/2014 (H5N1) (AB14 (H5N1)) and A/British 
Columbia/1/2015 (H7N9) (BC15 (H7N9)) are reported, the isolates had not been evaluated for 
their pathogenicity in animal models. In this study, we characterized the pathogenicity of AB14 
(H5N1) and BC15 (H7N9) and found that both strain isolates are highly lethal in mice. AB14 
(H5N1) caused systemic viral infection and proinflammatory cytokine gene expression in different 
organs. In contrast, BC15 (H7N9) replicated efficiently only in the respiratory tract and was a 
potent inducer for proinflammatory cytokine genes in the lungs. Our study provides experimental 
evidence to complement the specific human case reports and animal models for evaluating vaccine 




2.2 Introduction  
Influenza A virus (IAV) is a segmented RNA virus that infects a wide variety of species 
including human, avian, swine, equine, and sea mammals. The segmented genome and wide host 
range enable IAV to undergo antigenic variations through gene reassortment, a mechanism called 
antigenic shift, which is responsible for the emergence of pandemic influenza viruses. The lack of 
proofreading by the viral RNA-dependent RNA polymerase frequently results in point mutations 
throughout the viral genome (especially in HA and NA genes), which can lead to antigenic drift, 
a causative mechanism of annual influenza epidemics (Krammer et al., 2018; Webster, Bean, 
Gorman, Chambers, & Kawaoka, 1992). Additionally, IAV also poses a severe threat to public 
health through zoonotic infection, because avian IAVs can directly cross the species barrier and 
infect humans, with avian H5N1 and H7N9 viruses being such examples. The first report of human 
infection by the highly pathogenic avian influenza (HPAI) H5N1 virus was in 1997 in Hong Kong; 
after a short period of disappearance, the virus re-emerged in 2003 in China (Claas et al., 1998). 
Since then, sporadic human H5N1 viral infections have been reported in several countries, causing 
over 400 fatalities (WHO, 2019b). The low pathogenic avian influenza (LPAI) H7N9 virus 
circulated exclusively among poultry in China until 2013 when the first human infection was 
reported (Gao et al., 2013). Similar to the HPAI H5N1 virus, human infection by the H7N9 virus 
is also associated with a severe and fatal respiratory disease. To date, the H7N9 virus has caused 
a total of six epidemic waves, having infected over 1600 humans with 623 fatalities (WHO). 
In comparison to the human seasonal H1N1 and H3N2 viruses, the HPAI H5N1 virus 
induces more proinflammatory cytokines in the human alveolar and bronchial epithelial cells 
(Chan et al., 2005). H5N1 viral infection also results in the early and excessive infiltration of 
macrophages and neutrophils in the lungs of infected mice (Perrone, Plowden, Garcia-Sastre, Katz, 
& Tumpey, 2008). Animal and human studies have shown that the combinatorial effect of the 
unrestrained high-level virus infection together with hypercytokinemia is attributable to the 
increased pathogenesis of H5N1 disease (Abdel-Ghafar et al., 2008; de Jong et al., 2006). Although 
both H5N1 and H7N9 viral infections lead to fatality, the underlying mechanisms might be 
different (Meliopoulos et al., 2014). An ex vivo study showed that the human H7N9 virus 
replicated efficiently in human bronchial epithelial cells, alveolar epithelial cells, and alveolar 
macrophages, with high titres similar to that of the H5N1 virus (Chan et al., 2013). However, in 
animal studies, it has been reported that the H7N9 virus possesses a greater tropism for the 
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respiratory epithelium than the H5N1 virus, and is not capable of inducing hypercytokinemia, 
which is characteristic of H5N1 viral infection (Meliopoulos et al., 2014). Recently, a risk 
assessment of the fifth wave of H7N9 viral infection revealed that both the LPAI and HPAI H7N9 
viruses were isolated from humans. Compared to the LPAI H7N9, the HPAI H7N9 virus was 
found to possess enhanced virulence, tropism for the brain tissue, as well as the capability to 
transmit by air droplets, concluding that the HPAI H7N9 virus has gained the ability to cause an 
H7N9 pandemic (X. Sun et al., 2019). Thus, both H5N1 and H7N9 viruses are of significant 
pandemic concerns. 
Both HPAI H5N1 and LPAI H7N9 human infections in North America were reported in 
Canada, in 2014 and 2015 respectively, shortly after the patients returned from China (Maurer-
Stroh et al., 2014; Skowronski et al., 2016). The A/Alberta/01/2014 (H5N1) (AB14 (H5N1)) strain 
isolate caused a fatal infection, whereas the A/British Columbia/1/2015 (H7N9) (BC15 (H7N9)) 
strain isolate caused an influenza illness from which the patients recovered. Phylogenetic analysis 
revealed mutations on the receptor binding site of the HA gene in AB14 (H5N1), which facilitated 
the direct jump from avian species to humans (Pabbaraju et al., 2014). However, for BC15 (H7N9), 
the analysis showed the genome to be similar to those of previous human H7N9 isolates, carrying 
clinically relevant markers on HA, PB2, and NA genes (Skowronski et al., 2016). Although H5N1 
and H7N9 viruses have been intensively studied, the virulence of these avian-origin influenza 
strains isolated from these Canadian travelers has been overlooked. The purpose of this study was 
to experimentally investigate the pathogenicity as well as the cytokine and chemokine gene 
transcription profile of the AB14 (H5N1) and BC15 (H7N9) strain isolates. We report that both 
AB14 (H5N1) and BC15 (H7N9) strains are highly lethal in mice. AB14 (H5N1) caused a systemic 
viral infection as well as the proinflammatory cytokine and chemokine gene response in different 
organs. In contrast, the BC15 (H7N9) strain replicated efficiently only in the respiratory tract and 
was a potent inducer of proinflammatory cytokines in the lungs. Overall, our study not only 
provides experimental evidence to complement the human case report, but also offers valuable 
animal models for evaluating vaccine and antiviral candidates against the H5 and H7 potential 






2.3 Materials and methods 
2.3.1 Cells and viruses 
Madin-Darby canine kidney (MDCK, ATCC, #CRL-2936) cells were maintained in 
minimal essential medium (MEM, Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% 
fetal bovine serum (FBS, Sigma-Aldrich) and gentamycin (50 µg/mL, Bio Basic, Markham, ON, 
Canada). MDCK cells were maintained at 37ºC in a humidified 5% CO2 incubator. Influenza 
A/Alberta/01/2014 (H5N1) (AB14 (H5N1)) and A/British Columbia/01/2015 (H7N9) 
(BC15(H7N9)) were kind gifts from Dr. Yan Li at the National Microbiology Laboratory, Public 
Health Agency of Canada. The viruses were propagated in MDCK cells and titrated by plaque 
assay. Propagated viruses were sequenced, and no mutations were found according to the reference 
sequences. All infectious experiments were conducted in Biosafety Containment Level 3 at the 
International Vaccine Centre at the University of Saskatchewan, Canada, under the guidelines of 
the Public Health Agency of Canada (PHAC) and the Canadian Food Inspection Agency (CFIA). 
2.3.2 Ethics statement 
All animal procedures were approved by the University Animal Care Committee (UACC) 
and Animal Research Ethics Board (AREB) of the University of Saskatchewan on 31 August 2017 
(Animal Use Protocol #20170087) in accordance with the standards stipulated by the Canadian 
Council on Animal Care. 
2.3.3 Mouse experiments 
For this study, 84 six-week-old female BALB/c mice (Charles River Laboratories, Saint-
Constant, QC, Canada) were randomly divided into seven groups with 12 mice in each group. 
These groups were housed in separate cages in Biosafety Containment Level 3 seven days prior to 
infection. At seven weeks of age, each mouse was intranasally infected with 50 µL of 103 plaque 
forming unit (PFU), 104 PFU, and 105 PFU of either the AB14 (H5N1) or BC15 (H7N9) strain 
isolates. A group of mice was mock infected with PBS. The mice were monitored daily for body 
weight, and on days 2 and 5 post-infection (d.p.i), three mice from each group were euthanized, to 
which the lung and spleen tissues were collected for viral titration as well as cytokine and 
chemokine profiling. Brain tissues were collected from euthanized mice on either 6 or 7 d.p.i. The 
rest of the mice were humanely euthanized when they dropped below 20% of their initial body 
weight. 
2.3.4 Virus isolation and titration 
39 
 
Infectious lung, spleen, and brain tissues were processed immediately after collection as 
previously described (Pyo & Zhou, 2014). Briefly, the tissues were homogenized in MEM 
supplemented with Penicillin-Streptomycin (Gibco, Thermo Fisher, ON, Canada) in the 
TissueLyser II (Qiagen, Hilden, Germany) at 25 Hz for 5 min, followed by centrifugation at 5000× 
g for 10 min at 4 ºC. The supernatant was collected in screw-cap tubes and stored at −80 ºC for 
further titration. 
For virus titration by 50% tissue culture infective dose (TCID50) assay, MDCK cells were 
plated in 96-well plates, and the supernatants of homogenized tissues were serially diluted in MEM 
and incubated with cells for 1 h. The inoculum was removed and supplemented with MEM 
containing 0.2% BSA and 1 µg/mL TPCK-trypsin (Sigma-Aldrich). The development of 
cytopathic effects (CPE) was observed and recorded every 24 h until 96 h post-infection. The 
TCID50 titre of each infectious sample was calculated by the Spearman–Kärber algorithm (Kärber, 
1931; Spearman, 1908). 
2.3.5 RNA extraction and quantitative RT-PCR (qRT-PCR) 
Tissue samples of mice collected on 2 or 5 d.p.i. or upon necropsy were submerged into 
RNA later (Qiagen) and stored overnight at 4 ºC. The following day, the tissue samples were 
transferred to screw-cap tubes containing one 5 mm stainless steel bead (Qiagen) and 1 mL of 
TRIzol Reagent (Invitrogen, Carlsbad, CA, USA). The samples were homogenized using the 
TissueLyser II (Qiagen) at 25 Hz for 5 min, followed by centrifugation at 5000× g for 10 min at 4 
ºC. The supernatant was then transferred to new tubes for RNA extraction by the TRIzol method 
(Invitrogen). 
To determine mRNA levels of various cytokines and chemokines induced by AB14 (H5N1) 
and BC15 (H7N9) viral infection, qRT-PCR was performed on total RNA of the samples collected 
from mice infected with 103 PFU of the respective virus, as previously described with the following 
modifications (G. Liu et al., 2018). Briefly, a 500 µg portion of RNA was reverse transcribed with 
oligo (dT) and SuperScript III Transcriptase (Invitrogen) to obtain total mRNA. qPCR was 
performed on a StepOnePlusTM Real-Time PCR system (Applied Biosystems, CA, USA) with the 
Power SYBR Green PCR Master Mix (Applied Biosystems). Cytokine mRNA levels were 
normalized to that of the housekeeping gene HPRT and expressed using the ∆∆CT method relative 




Table 2.1 List of primers used in RT-qPCR studies in mice. 
 
























All primers have been validated to have greater than 95% of amplification efficiency. The 
expression levels of cytokine mRNA were normalized to the expression of the housekeeping gene 




The left side of the lung was fixed with 10% natural buffered formalin, processed for 
hematoxylin and eosin (H&E) staining, and assessed in a blind manner by a board-certified 





2.4.1 Survival rate and body weight loss of mice infected with the HPAI H5N1 and LPAI 
H7N9 strain isolates 
To determine the pathogenicity of the AB14 (H5N1) and BC15 (H7N9), BALB/c mice 
were intranasally inoculated with PBS or either AB14 (H5N1) or BC15 (H7N9) at three different 
doses (103 PFU, 104 PFU, and 105 PFU). Survival and body weight loss were monitored for 10 
days (Figure 2.1). Mice infected with PBS survived the duration of the trial and gained weight as 
the days progressed. In contrast, mice infected with the different doses of either AB14 (H5N1) or 
BC15 (H7N9) showed rapid body weight loss and severe mortality rates. Mice infected with 104 
PFU or 105 PFU of AB14 (H5N1) exhibited rapid weight loss greater than 20% of their initial 
body weight within four days post-infection (d.p.i.). Furthermore, over 60% of mice infected with 
105 PFU of AB14 (H5N1) had succumbed by 4 d.p.i. (Figure 2.1A and B). By 5 d.p.i., 100% of 
mice infected with 104 PFU and 105 PFU were humanely euthanized due to severe body weight 
loss. Albeit mice infected with 103 PFU displayed the slowest rate of body weight loss, they all 
reached a humane endpoint by 6 d.p.i. With regard to BC15 (H7N9), mice infected with 103 PFU 
displayed the slowest decline of body weight, losing over 20% of their initial body weight by 8 
d.p.i. Furthermore, 50% of mice infected with 103 PFU reached a humane endpoint by 7 d.p.i., 
while the other 50% reached this endpoint by 8 d.p.i. (Figure 2.1C and D). In contrast, mice 
infected with 104 PFU and 105 PFU had steeper body weight losses and higher mortality rates. In 
the 104 PFU group, 100% of mice reached a humane endpoint by 6 d.p.i., while in the105 PFU 
group, 50% of the mice by 4 d.p.i. and the other 50% by 5 d.p.i. reached this endpoint. These 
results demonstrate that both the AB14 (H5N1) and BC15 (H7N9) strain isolates are highly 










Figure 2.1  Survival rate and body weight loss for the AB14 (H5N1) and BC15 (H7N9) strain 
isolates. 
The survival rates for (A) AB14(H5N1) and (C) BC15(H7N9) as well as body weight changes for 
(B) AB14(H5N1) and (D) BC15(H7N9) were determined in BALB/c mice (n=6 per group) 
infected with 103 PFU, 104 PFU, and 105 PFU of the two different strain isolates. 
 
 
2.4.2 Histopathology of the Mouse Lung 
To examine the levels of pulmonary pathology from AB14 (H5N1) and BC15 (H7N9) 
infection, we performed a histopathology study on the lungs of mice infected with 103 PFU that 
reached a humane endpoint on 6 or 7 d.p.i. Mice infected with both AB14 (H5N1) and BC15 
(H7N9) strain isolates showed bronchointerstitial pneumonia, with vasculitis (Figure 2.2). 
Specifically, the walls of the arterioles in infected mice were found to be infiltrated with 






























































































































inflammatory cells and contained some necrotic debris (Figure 2.2D and G). In addition, viral 
infection also led to moderate damage to the mice alveoli and bronchioles. In the alveoli of infected 
mice, we found moderate thickening of the alveolar walls due to congestion as well as some 
inflammatory infiltrate (Figure 2.2E and H). The alveolar space was filled with edema and 
contained small to moderate numbers of mixed neutrophils and macrophages. Occasionally, 
hyaline membranes lining the alveoli were observed (Figure 2.2E). Multifocally, the bronchiolar 
epithelium was necrotic, and the lumen was filled with some necrotic debris and inflammatory 
cells as seen in the alveolar space (Figure 2.2F and I). 
 
Figure 2.2 Lung histopathology of mice after infection with AB14 (H5N1) and BC15 (H7N9) 
strain isolates. 
Lung samples were fixed, sectioned, and stained with hematoxylin and eosin. (A-C) Tissues from 
mock-infected lungs. (D-F) Tissues from mice infected with AB14 (H5N1) showing infiltration of 










epithelium affected by necrosis. (G-I) Tissues from mice infected with BC15 (H7N9) showing 
necrotic debris and inflammatory cells in the (G) wall of the arteriole, (H) collapsed alveoli, as 
well as degeneration and necrosis of the (I) bronchiolar epithelium. Scale bar represents 100 µm. 
 
 
2.4.3 Replication efficiency of the HPAI H5N1 and LPAI H7N9 strain isolates in different 
organs of mice 
To investigate the replication efficiency and tissue tropism of both strain isolates, mouse 
lung, spleen, and brain tissues were collected at predetermined days, as well as when the mice 
reached a critical endpoint (Figure 2.3). In all groups of mice infected with AB14 (H5N1), the 
peak lung viral titres were reached by 2 d.p.i., which remained at high levels throughout the trial. 
The mean titres on 5 d.p.i. were 107.2, 106.4, and 106.7 TCID50/g for 103 PFU, 104 PFU, and 105 
PFU, respectively (Figure 2.3A). Brain samples taken from the lowest dose group (103 PFU) had 
very high viral titres on 6 d.p.i., with a mean virus titre of 107 TCID50/g (Figure 2.3C). Note that 
the brain samples were only harvested at the endpoint. Spleen viral titres remained at an 
approximate level of 102.5 TCID50/g from 2 d.p.i. until 5 d.p.i. (day 2: 102.64 TCID50/g, day 5: 102.46 
TCID50/g) in the mice infected with 105 PFU of the AB14 (H5N1) strain isolate (Figure 2.3D). 
Interestingly, spleen viral titres were not detected for the two lower dose groups (103 PFU and 104 
PFU). 
In BC15 (H7N9) viral infected lung, the 103 PFU group reached a titer of approximately 
106.5 TCID50/g by 2 d.p.i. and remained at this titer throughout the duration of the trial. The 104 
PFU group displayed a similar trend, with high titers present at 2 d.p.i. (108 TCID50/g), which 
decreased by 5 and 6 d.p.i. (106.5 TCID50/g). The 105 PFU group had the highest titer at 2 d.p.i. 
(108 TCID50/g), which remained at this level throughout the duration of the trial (Figure 3B). The 
BC15 (H7N9) strain isolate was not detected in the spleen and brain of mice infected by all three 









Figure 2.3 Viral titration of the mouse lung, spleen, and brain for the AB14 (H5N1) and 
BC15 (H7N9) strain isolates. 
Mice were intranasally infected with 103 PFU, 104 PFU, or 105 PFU of AB14 (H5N1) or BC15 
(H7N9). The lung, spleen, and brain tissues were collected and homogenized for virus titration by 
TCID50 assay. Lung viral titration from (A) AB14 (H5N1) and (B) BC15 (H7N9) infection for all 
doses. Brain viral titration from (C) AB14 infection (H5N1). Spleen viral titration from (D) AB14 
(H5N1) infection. Please note that BC15 (H7N9) was not detected in the spleen and brain of mice 
infected by all three doses. 
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To understand the pathogenesis and immune response to AB14 (H5N1) and BC15 (H7N9) 
viral infection, we assessed the innate immune receptor retinoic acid-inducible gene I (RIG-I), as 
well as the cytokine and chemokine gene expression in the lungs and brains of mice infected with 
the lowest dose (103 PFU) of both strain isolates by qRT-PCR. To start, we investigated a group 
of genes that encode interferons as well as the innate immune sensor RIG-I, a major pattern 
recognition receptor that recognizes influenza viral infection and activates the interferon response 
(Opitz et al., 2007). Interferon (IFN)-α and IFN-β are both type I interferons which play essential 
roles in antiviral defense (Taniguchi & Takaoka, 2002). IFN-γ is a type II interferon that is the first 
cytokine produced in response to foreign invaders and is an important activator of macrophages 
and natural killer (NK) cells. IFN-γ also has antiviral activity and inhibits the proliferation of Th2 
cytokines (Interleukin (IL)-4, IL-5, and IL-6) (Tau & Rothman, 1999). In the AB14 (H5N1) 
infected lungs (Figure 2.4A), gene expression of RIG-I peeked on 2 d.p.i., which then decreased 
by 5 and 7 d.p.i. IFN-α gene expression was drastically upregulated on 2 d.p.i., and then sharply 
dropped on 5 and 7 d.p.i. IFN-β mRNA levels increased over 60-fold on 2 d.p.i., which then 
slightly decreased but remained at moderately high levels on 5 and 7 d.p.i. The type I IFN gene 
transcription levels showed similar upregulating patterns in concordance with that of RIG-I. IFN-
γ had the highest upregulation by 2 d.p.i., which dropped moderately by 5 d.p.i., and then increased 
slightly by 7 d.p.i. The transcription of the gene encoding interferon-gamma-inducing protein 10 
(IP-10), a cytokine produced in response to IFN-γ, was significantly upregulated (over 2000-fold) 
on 2 d.p.i., and then remained at relatively high levels, consistent with the IFN-γ mRNA 
upregulation pattern. Next, we profiled the gene transcription of proinflammatory (Tumor necrosis 
factor (TNF) α, IL-6, IL-1β, and IL-18) and anti-inflammatory (IL-10) cytokines. TNFα is a 
proinflammatory cytokine produced in response to the foreign invasion and is often the main 
cytokine produced by macrophages following infection (Idriss, Naismith, & technique, 2000). IL-
6 and IL-1β are the main contributors to severe lung inflammation in both humans and poultry 
infected by influenza virus (Saito et al., 2018). Both TNFα and IL-6 mRNA were markedly 
upregulated upon AB14 (H5N1) infection and remained at these elevated levels. IL-1β mRNA was 
upregulated 7-fold on 2 d.p.i., which then returned to slightly higher levels than that of the 
uninfected control. IL-18 mRNA remained at mock levels upon infection. On the contrary, the 
mRNA level of the anti-inflammatory cytokine IL-10 was gradually upregulated after infection, 




Figure 2.4 Innate immune receptor RIG-I, as well as cytokine and chemokine gene 
transcription levels in the lungs of mice infected with the AB14 (H5N1) and BC15 (H7N9) 
strain isolates.  
Cytokine and chemokine mRNA levels of RIG-I, IFN-α, IFN-β, IFN-γ, IP-10, TNFα, IL-6, IL-
1β, IL-18, and IL-10 from virus-infected lungs with (A) AB14 (H5N1) and (B) BC15 (H7N9) 
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(n=3 mice per virus group) were measured by qRT-PCR. Samples were harvested on the 
indicated d.p.i.; each sample was tested in triplicate. 
 
 
In the lungs of BC15 (H7N9) infected mice, substantially upregulated mRNA levels of 
interferon genes (IFN-α, IFN-β, and IFN-γ), interferon responsive cytokine gene (IP-10), and 
proinflammatory cytokine genes (TNFα and IL-6) were obtained on 2 d.p.i. compared to the 
uninfected control (Figure 2.4B). IFN-α, and IFN-β mRNA levels substantially dropped by 7 d.p.i., 
whereas mRNA levels of RIG-I, IFN-γ, and TNFα remained relatively unchanged throughout the 
duration of the trial. Similar to what we observed for AB14 (H5N1), the IL-18 gene transcript was 
not upregulated in response to viral infection, whereas the gene transcription of the anti-
inflammatory cytokine IL-10 dramatically increased from 2 to 7 d.p.i. 
Besides cytokine and chemokine gene transcription analysis in the lungs of viral infected 
mice, we also analyzed select cytokine transcription levels in the brains of mice harvested at the 
endpoint. In the brains of mice infected with AB14 (H5N1), the transcription of IFN genes (IFN-
α, and IFN-γ) as well as proinflammatory cytokine genes (TNFα, IL-6, and IL-1β) was 
dramatically upregulated compared to the uninfected control (Figure 2.5A). Among all genes 
activated in the brain tissue upon infection, IFN-γ and TNFα were the most highly transcribed 
cytokines associated with HPAI AB14 (H5N1) infection. Similar to the cytokine regulation 
observed in the mouse lung, IL-18 transcripts did not change upon AB14 (H5N1) infection when 
compared to the uninfected control (Figure 2.5A). In contrast, the brains of mice infected with 
BC15 (H7N9) had only moderate upregulation of IFN-α, IFN-γ, and IL-6 gene transcription, which 
was marginal compared to the degree of upregulation observed in the AB14 (H5N1) viral infected 
brain. The transcripts of the other inflammatory cytokine genes, TNFα, IL-1β, and IL-18, did not 





Figure 2.5 Cytokine gene transcription profile in the brains of mice infected with the AB14 
(H5N1) and BC15 (H7N9) strain isolates.  
Cytokine transcription levels of IFN-α, IFN-γ, TNF-α, IL-6, IL-1β, and IL-18 from virus-infected 
brains with (A) AB14 (H5N1) and (B) BC15 (H7N9) (n=3 mice per virus group). Samples were 
harvested on the indicated d.p.i; each sample was tested in triplicate. 
 
 
2.5 Discussion and Conclusions 
Following the reporting of the human HPAI (H5N1) and LPAI (H7N9) infection in Canada, 
the characterization on the causative strain isolates associated with these human infection cases, 
AB14 (H5N1) and BC15 (H7N9), was reported. Pabbaraju et al. analyzed the full genome of AB14 
(H5N1) and assessed its molecular markers of pandemic risk (Pabbaraju et al., 2014). Skowronski 
et al. conducted the serological and phylogenetic analysis of BC15 (H7N9), reporting that this 
virus belongs to the clade W2-C, which clusters with both the 2014–2015 H7N9 human isolates 
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from the Jiangsu, Zhejiang, and Fujian Provinces of China as well as the 2014 chicken isolated 
from Jiangsu Province (Skowronski et al., 2016). Despite the analysis on these two Canadian 
isolates, the infectious and immunological properties as well as the histopathological correlation 
to disease remained elusive. In this study, we aimed to fill this knowledge gap, and to provide 
insightful information on the pathogenesis of the AB14 (H5N1) and BC15 (H7N9) strain isolates 
in mice. 
To ensure that the AB14 (H5N1) and BC15 (H7N9) strain isolates would induce disease 
in mice, we chose to infect them with three different doses (103 PFU, 104 PFU, and 105 PFU). We 
found that even at the lowest dose (103 PFU), both isolates were lethal to mice. AB14 (H5N1) 
caused all mice to reach a humane endpoint by 6 d.p.i., whereas BC15 (H7N9) infected mice 
survived one to two days longer than the mice infected with AB14 (H5N1). This observation is in 
contrast to the various seasonal or the 2009 pandemic influenza viruses (Groves et al., 2018; Rowe 
et al., 2010). Groves et al. reported that mice infected with 5×103 PFU of influenza 
A/England/195/2009 (H1N1) showed mild weight loss over 7 days, whereas mice infected with 
103 PFU of influenza A/England/691/2010 (H3N2) did not show any signs of disease (Groves et 
al., 2018). In the study reported by Rowe et al., infection of BALB/c mice with 104 EID50 of the 
2009 pandemic virus did not cause any death when using 20% total body weight loss as an endpoint 
(Rowe et al., 2010). Furthermore, we could detect the AB14 (H5N1) strain in multiple organs, 
including the lung, spleen, and brain, with consistently high titres in the lung and brain tissues. 
However, we could only detect the BC15 (H7N9) strain in the mouse lung, with no detectable 
virus in the spleen and brain by TCID50 assay. These results are in agreement with the previous 
reports that while H5N1 virus has the ability to replicate systemically and spread efficiently to 
non-respiratory tissues, H7N9 virus replicates well in the upper respiratory tract, covering the nasal 
passages, nasopharynx-associated lymphoid tissues (Meliopoulos et al., 2014), human bronchus, 
and the lungs (Chan et al., 2013). Research has shown that avian IAV strains need to acquire 
adaptation mutations in order to be infectious in mammals, with one such adaptation being in the 
polymerase, PB2. This adaptation resides at the amino acid at position 627 of PB2 and determines 
the viral replication efficiency in different hosts. It is well characterized that avian strains carry a 
glutamic acid (E) at this position referred to as 627E, whereas mammalian strains carry a lysine 
(K), namely, 627K (Hatta, Gao, Halfmann, & Kawaoka, 2001). The BC15 (H7N9) strain isolate 
consists of PB2 encoding 627K, which may explain its ability to replicate well in the human 
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respiratory tract. In contrast, the AB14 (H5N1) strain isolate consists of PB2 possessing the avian 
signature, namely, 627E. However, our data have shown that while AB14 (H5N1) replicates 
efficiently without any adaptation in mice, it replicates less efficiently in tissue culture (Lu and 
Zhou unpublished data). In addition to the PB2 protein, HA protein is also a key viral factor that 
determines whether an avian virus can replicate well in mammals. It is reported that AB14 (H5N1) 
HA contains two novel mutations, R189K and G221R, which are located in the immediate 
receptor-binding pocket (Pabbaraju et al., 2014). It was speculated that these mutations arose in an 
avian H5N1-infected patient, which was also associated with severe illness and spread of the virus 
to the brain. We observed that the AB14 (H5N1) strain isolate replicated efficiently in the mouse 
brain, which will provide a model for further investigation of the functional role of G221R in avian 
influenza HA contributing to viral pathogenesis in mammals. 
Research has shown that the dysregulation of the innate immune responses that results in 
an unusual proinflammatory cytokine production often contributes to the pathogenicity of both the 
HPAI H5N1 virus and the 1918 Spanish Flu pandemic virus (Cilloniz et al., 2009; Perrone et al., 
2008). Our data show that although at different magnitudes, infection by both AB14 (H5N1) and 
BC15 (H7N9) induced dramatically elevated levels of interferon genes and proinflammatory 
cytokine gene expression in the lungs. These levels peaked on 2 d.p.i., and then decreased but 
remained at moderate levels as the infection progressed. Concomitantly, both strain isolates 
induced increased gene expression of the anti-inflammatory cytokine IL-10, which peaked on 6 
and 7 d.p.i., for both the AB14 (H5N1) and BC15 (H7N9) strain isolates, respectively. There has 
been evidence showing IL-10 to inhibit several proinflammatory cytokines and chemokines 
(Couper, Blount, & Riley, 2008), and that it may therefore actually hinder clearance of the virus 
(Frensing et al., 2016). When comparing the transcription levels of various cytokines, it was found 
that most cytokine genes were sharply upregulated in the tens- to hundreds-fold. Interestingly, the 
two inflammatory cytokines IL-1β and IL-18, whose maturation is regulated by inflammasome 
activity (Kaplanski, 2018), were not significantly upregulated at the mRNA level; IL-1β mRNA 
was only moderately upregulated, whereas IL-18 mRNA was not upregulated at all. This finding 
thus warrants further investigation into the mature IL-1β and IL-18 protein levels, in order to 
understand their roles in mediating avian IAV-induced pathogenesis. Interestingly, it has been 
reported that in comparison to other H5N1 strain isolates that are associated with severe human 
respiratory disease, H7N9 strains isolated from human infections from 2013 to 2015 are poor 
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proinflammatory cytokine and chemokines inducers in mammalian models (Belser et al., 2016). 
However, our results showed that BC15 (H7N9) is a potent inducer of proinflammatory cytokines 
in the mouse lung. This finding is consistent with the study of human patients infected with the 
H7N9 virus, where elevated cytokine and chemokine production was observed (Chi et al., 2013). 
With regard to the cytokine gene expression in the mouse brain, we found that AB14 (H5N1) 
dramatically upregulated IFN-α, IFN-γ, TNF-α, and IL-6 transcription in the brains of mice that 
reached a humane endpoint. This finding possibly indicates cytokine hyperinduction in the brains 
of mice infected with AB14 (H5N1), which may contribute to the pathogenesis. In contrast, only 
moderate upregulation of both IFN-γ and IL-6 transcripts was observed in the brains of mice 
infected with BC15 (H7N9). This finding reflects the viral titres found in the infected brains of the 
mice, such that while mice infected with AB14 (H5N1) had high titres, mice infected with BC15 
(H7N9) had no detectable virus in the brain. 
Taken together, we showed that the AB14 (H5N1) strain isolate replicates efficiently 
without prior adaptation not only in the mouse lung, but also in other non-respiratory tissues such 
as the spleen and brain. The high viral load and hypercytokinemia in multiple organs contributed 
to the severity of the disease associated with AB14 (H5N1) infection. Similarly, the BC15 (H7N9) 
strain is also highly pathogenic in mice, but its replication seemed to be more constrained to the 
respiratory tract. The severity of both AB14 (H5N1) and BC15 (H7N9) disease as well as the 
significant lung pathology observed may be a result of the unusual upregulation of 
proinflammatory cytokines including TNFα, IP-10, and IL-6. Our findings not only contribute to 
a better understanding of the pathogenesis of the strain isolates associated with Canadian human 
cases of avian H5N1 and H7N9 virus infection, but also provide animal models for testing vaccine 
and antiviral candidates for viruses that are of significant public health concerns. 
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TRANSITIONS BETWEEN CHAPTER 2 AND CHAPTER 3 
In chapter 2, I established a mouse disease model to test the infection of AB14 (H5N1) 
virus. My results showed that intranasal inoculation of 103 PFU of AB14 (H5N1) to mice could 
lead to rapid weight loss and 100% mortality rate without the need of adaptation. Furthermore, 
AB14 (H5N1) virus caused systematic infection in multiple organs, including lung, spleen and 
brains, with dysregulation of proinflammatory cytokines and chemokines in lung and brains. These 
results, for the first time, provide experimental data to complete the human case report of the 
Canadian HPAI H5N1 isolate and offer a valuable animal model for further vaccination study.  
In the following chapter, I focused on design, expression and purification of HA 
immunogens in two expression systems; characterization of the immunogens in vitro; using the 
mouse model I established for AB14 (H5N1) to evaluate the immune responses and protection 
efficacy of the HA immunogens with or without the TriAdj.  
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3.1  Abstract 
The highly pathogenic avian influenza (HPAI) H5N1 viruses and their spillover into the 
human population pose substantial economic burdens and public health threats. Here we developed 
a novel H5 influenza vaccine to improve the pandemic preparedness. The hemagglutinin (HA) of 
HPAI H5N1 virus A/Alberta/01/2014 (AB14) was produced using both mammalian (m) and 
bacterial (b) expression systems. The purified recombinant proteins were formulated with a 
proprietary adjuvant (TriAdj) and their efficacy as vaccine candidates was evaluated in mice. 
Intramuscular delivery of two doses of TriAdj formulated mammalian expressed HA (m-
HA/TriAdj) provided full protection against a lethal challenge of AB14 in mice; in contrast 
bacterially expressed HA with TriAdj (b-HA/TriAdj), b-HA without adjuvant or m-HA without 
adjuvant resulted in no protection in immunized mice. Furthermore, m-HA/TriAdj elicited 
significantly higher levels of balanced Th1 and Th2 responses and neutralizing antibody titres. All 
of the mice in this group survived a lethal AB14 H5N1 challenge and showed no signs of disease 
or infection as demonstrated by no loss of body weight or detectable virus in the lungs. Our results 
suggest that m-HA formulated with TriAdj has potential to protect against pandemic H5N1 in the 
event of its cross over to the human host.  
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3.2 Introduction  
Influenza A virus (IAV) is a significant health threat to the human population. It infects a 
wide host range, including waterfowl, poultry, swine, horse, dog, cat, human and several other 
mammal species (Short et al., 2015). Aquatic birds are natural reservoirs for IAVs, with 16 HA 
and 9 NA subtypes of IAVs being identified thus far (Fouchier et al., 2005; Sato et al., 2019). 
Increasing risk of zoonotic disease outbreaks exists due to the interspecies spillover of the highly 
pathogenic avian influenza viruses (HPAI) from avian species to human hosts. To date, 860 HPAI 
H5N1 human infection cases have been reported in 16 countries, of which around 52% were fatal 
(WHO, 2019c). The transmission of HPAI H5N1 virus from birds to humans occurs through either 
direct contact with infected poultry or indirect contact by exposure to the contaminated 
environment (Van Kerkhove et al., 2011). The adaptive mutations acquired by HPAI H5N1 viruses 
may lead to increased transmission efficiency from birds to humans; alternatively, the acquisition 
of human-to-human transmission ability of the virus might result in a devastating influenza 
pandemic. Although antiviral drugs have some effect in treating influenza infection, vaccination 
is still the most effective intervention to prevent possible pandemic outbreaks. However, 
conventional egg-based vaccine production strategy takes up to six months for vaccine 
development, during which the antigenically-distinct pandemic viruses are allowed to spread in 
the naïve population leading to a rapid disease progression (Krammer & Palese, 2015). Traditional 
inactivated vaccines against zoonotic avian influenza viruses often suffer from low 
immunogenicity due to the intrinsic  poor antigenicity of avian influenza viruses, or they are poor 
inducers of cellular immunity (R. D. de Vries, Herfst, & Richard, 2018). 
Currently, several human H5N1 subunit pre-pandemic stockpiling vaccines are under 
development (WHO, 2019a). Clinical studies and animal studies have shown that HA of influenza 
H5 subtype is a weak antigen and is less immunogenic; co-formulation with adjuvant or higher 
antigen dose in the vaccine is necessary to enhance its immunogenicity (R. B. Belshe et al., 2014; 
Frey et al., 2019; W. Keitel et al., 2010; Sun et al., 2017; S. H. Wang et al., 2019). Adjuvants have 
been used in vaccines for more than 90 years and significantly enhance immune responses towards 
vaccine antigens, particularly for viral antigens with poor immunogenicity (Cohet et al., 2019; Di 
Pasquale, Preiss, Tavares Da Silva, & Garcon, 2015). In FDA-approved vaccines, limited 
adjuvants are employed in vaccines for human, which include aluminum salts, MF59, AS01, AS03, 
AS04, and CpG ODN (Shi et al., 2019). We developed Triple Adjuvant (TriAdj) which consists 
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of three components: poly (I:C), a ligand of the toll-like receptor-3 (TLR3); IDR-1002, an innate 
defense regulatory peptide; and poly[di(sodium carboxylatoethylphenoxy)] phosphazene (PCEP), 
a synthetic polymer (Andrianov, Marin, & Chen, 2006; Niyonsaba et al., 2013; Sadat, Snider, Garg, 
Brownlie, & van Drunen Littel-van den Hurk, 2017). Formulation of TriAdj with human viral and 
bacterial antigens including human respiratory syncytial virus (RSV) and Bordetella pertussis 
induced efficient and long-lasting immune responses in animal models such as mice, sheep, and 
pigs (Garg et al., 2014; Garg, Latimer, Gerdts, Potter, & van Drunen Littel-van den Hurk, 2015; 
Polewicz et al., 2011). However, whether TriAdj can enhance the immunogenicity of influenza 
antigens has not yet been determined. 
The glycosylation status of HA, particularly glycan quantity or quality, is closely 
associated with the induction of virus-specific antibody responses. It has been reported that large 
glycans can mask conserved epitopes on HA resulting in reduced immunogenicity compared to 
HA with a single glycan or without glycosylation (C. C. Wang et al., 2009). However, 
glycosylation may be required for the correct conformation of the protein and essential for the 
expression of protective epitopes which elicit neutralizing antibodies. Compared to N-glycosylated 
HA antigen, non-glycosylated HA antigen showed relatively low induction of antigen-specific 
antibodies in vivo (Hutter et al., 2013). Thus, glycosylation is an important parameter to be 
considered in the design of HA-based subunit vaccines.  
In this study, we aimed to develop a new subunit H5 influenza vaccine to achieve better 
immune protection against HPAI H5N1 virus infection. Given the roles of glycosylation and 
adjuvant in determining the immunogenicity of antigens, we compared H5 HA antigens expressed 
in either mammalian or bacterial system and formulated with or without the TriAdj, with respect 
to their immunogenicity and protective capacity against lethal viral challenge in mice. Our results 
showed that the bacterially expressed HA (b-HA) did not provide protection against an H5N1 
lethal challenge, regardless of the presence of TriAdj. In contrast, vaccination with the 
mammalian-expressed recombinant HA antigen (m-HA) formulated with TriAdj elicited 
significantly higher levels of IgG1 and IgG2a, as well as neutralizing antibodies in the serum 
compared to all the other vaccine combinations, and protected mice from a lethal challenge with 






3.3 Materials and methods 
3.3.1 Cells and Viruses 
Human embryonic kidney (HEK293T, ATCC, #CRL-3216) cells were maintained in 
Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma, Oakville, ON, Canada) supplemented 
with 10% fetal bovine serum (FBS, Sigma) and 50µg/ml gentamycin (Bio Basic Canada, Toronto, 
ON, Canada). The 293T cell line stably expressing the recombinant HA protein was cultured in 
DMEM supplemented with 10% FBS, antibiotic-antimycotic (Gibco, Grand Island, NY, USA) and 
1 µg/ml puromycin (Invivogen, San Diego, CA, USA) for maintaining.  
Influenza A/Alberta/01/2014 (H5N1) [AB14 (H5N1)] (GISAID EpiFlu database ID: 
EPI_ISL_154130) was kindly provided by Dr. Yan Li at the National Microbiology Laboratory, 
Public Health Agency of Canada. The virus was propagated in MDCK cells and the titre was 
measured by plaque assay. All the H5N1 virus infection experiments were conducted in Biosafety 
Containment Level 3 at the International Vaccine Centre at the University of Saskatchewan, 
Canada under the guidelines of Public Health of Canada and the Canadian Food Inspection Agency.  
3.3.2 Protein production 
The HA amino acid sequence is derived from AB14 (H5N1). The HA gene was codon-
optimized for mammalian expression and was synthesized based on the HA amino acid sequence 
on EpiFlu databases (EPI500771) by GenScript (Piscataway, NJ, USA). The polybasic cleavage 
site on the HA gene was mutated form PQRERRRKRG to PQTRG to minimize unnecessary 
cleavages in producing the HA proteins. The last 10 amino acids at the C terminus of the HA 
ectodomain was deleted as this was observed to substantially increase the yield of secreted 
recombinant protein. For mammalian expression, the HA coding sequence with N-terminal tissue 
plasminogen activator (TPA) signal peptide and C-terminal his12-tag, was cloned into an episomal 
expression vector pEB4.3 (accession number: MG182339). The coding sequence was proceeded 
by a Kozak sequence and was cloned downstream of a human CMV promoter and intron IA 
contained within the vector; the resulting plasmid construct was named pEB-HA. For Bacterial 
expression, the HA sequence encoding AA 16-521 of AB14 HA fused with an N terminal His6 tag 
was cloned downstream of a T7 promoter contained within a pET vector (pET30a.1); the resulting 
construct was named pET-HA.  




Table 3.1 List of expression plasmids used in Chapter  
 
Their expression level and location are summarized in Table 3.1. The construct has the most 
abundant supernatant expression is bolded in the table and used in the study. The original signal 








HA (1-52, 320-531 
aa) 1150 cell lysate No secretion 
Mini HA mut 
HA (1-52, 320-531 
aa) 1151 cell lysate No secretion 




HA (17-52, 320-531 
aa) 1180 cell lysate No secretion 
Mini HA mut 
HA (17-52, 320-531 
aa) 1181 cell lysate No secretion 
HA ectodomain HA (17-531 aa) 1147 cell lysate No secretion 





HA with C-term 
Δ10 aa (Δpb) 
HA (17-521 aa Δ339-





HA with C-term Δ20 
aa (Δpb) 
HA (17-511 aa Δ339-
344 aa) 1286 cell lysate No secretion 
HA with C-term Δ40 
aa (Δpb) 
HA (17-491 aa Δ339-
344 aa) 1287 cell lysate No secretion 
HA with C-term Δ60 
aa (Δpb) 
HA (17-471 aa Δ339-




HA ectodomain HA (17-531 aa) 1232 cell lysate No secretion 
HA ectodomain Δpb 
HA (17-531 aa Δ339-
344 aa) 1233 cell lysate No secretion 
Mini HA 
HA (17-52, 320-531 
aa) 1234 cell lysate No secretion 
Mini HA Δpb 
HA (17-52, 320-531 
aa Δ339-344 aa) 1235 cell lysate No secretion 
HA1 HA (17-338 aa) 1294 cell lysate No secretion 
HA with C-term Δ10 
aa (Δpb) 
HA (17-521aa Δ339-





HA with C-term Δ20 
aa (Δpb) 
HA (17-511 aa Δ339-
344 aa) 1290 cell lysate No secretion 
HA with C-term Δ40 
aa (Δpb) 
HA (17-491 aa Δ339-
344 aa) 1291 cell lysate No secretion 
HA with C-term Δ60 
aa (Δpb) 
HA (17-471 aa Δ339-
344 aa) 1292 cell lysate No secretion 
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peptide of HA constructs with the N terminus 17aa deletion are replaced with TPA signal peptide 
on the vector.  
 
 
3.3.3 Protein production 
HEK293T cells (ATCC) were maintained in DMEM (Sigma) supplemented with 10% FBS 
(Sigma) and 50µg/ml gentamycin (Bio Basic Canada). HEK293T cells were transfected with pEB-
HA using TransIT-LT1 (Mirus, Madison, WI, USA) according to the manufacturer’s protocol. 
Stable maintenance of the episomal vector was selected by addition of puromycin (1 µg/ml) 48 
hours post transfection. Cells were grown in Hyclone CDM4HEK293 supplemented with 
GlutaMAX (Gibco), antibiotic-antimycotic, 1 µM sodium pyruvate, and 1 µg/ml puromycin 1 
µg/ml (Invivogen) for 48 hours to produce H5 HA protein. Protein was purified from the 
supernatant with NI-NTA agarose affinity chromatography (Qiagen, Toronto, ON, Canada) and 
dialyzed against phosphate-buffered saline (PBS buffer).  
For bacterial protein expression, the pET-HA construct was transformed into BL21 (DE3). 
Cells were grown to mid-log phase in LB medium and expression of recombinant HA was induced 
by the addition of 0.5 mM IPTG (Sigma-Aldrich, St. Louis, MO, USA) followed by growth with 
vigorous aeration at 26˚C for 5 hours. Bacteria were collected by centrifugation, resuspended in 
lysis buffer (150 mM NaCl, 25 mM Tris-HCl, 0.5% Triton X-100, protease inhibitor (Cell 
Signaling, #5871S, Whitby, ON, Canada), pH 8.0) and broken using an emulsiflex C3 
homogenizer (Avestin, Ottawa, ON, Canada). After disruption, the lysate was centrifuged at 
13,000 rpm for 40 min, and the pellet was collected and stored at −20C; all recombinant HA was 
determined to be expressed as inclusion bodies within the pellet fraction. The recombinant HA 
was solubilized by resuspension in denaturation buffer (500 mM NaCl, 25 mM Tris–HCl, 5 mM 
imidazole, 8 M urea, pH 7.9). After centrifugation at 13,000 rpm for 40 min to remove insoluble 
material, b-HA was purified using NI-NTA agarose according to the manufacturer’s instructions. 
Recombinant b-HA was eluted with elution buffer (500 mM NaCl, 25 mM Tris-HCl, 500mM 
imidazole, 8 M Urea, pH 7.9). The 10 ml eluted b-HA was loaded into a syringe with a 27-gauge 
needle and allowed to drop by gravity into 2L of refolding buffer (50 mM glycine, 5 mM EDTA, 
5 mM DTT, pH 9.0) with stirring at 4C for 48 hours. The diluted protein was concentrated using 
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an Amicon Ultra-15 centrifugal filter (10 kDa) (Millipore, Burlington, MA, USA) and dialyzed 
for 48h at 4C against PBS buffer. 
3.3.4 Circular Dichroism (CD) Spectroscopy 
The secondary structures of the m-HA and the b-HA protein were investigated by CD 
spectroscopy with Chirascan Plus CD Spectrometer (Applied Photophysics, Leatherhead, UK). 
Each of the purified protein was diluted into PBS buffer and subjected to CD analysis. CD 
spectrum was measured between 280-170 nm at 20˚C. The secondary structure content of each 
protein was analyzed with Chirascan software based on its CD spectrum. 
3.3.5 Animal vaccination and challenge 
Fifty-five four-week-old female BALB/c mice (Charles River Laboratories, Saint-Constant, 
QC, Canada) were divided into 5 groups with 11 mice per group. Acclimatization was held in 
Biosafety Level 2 containment 5 days prior to vaccination. At day 0, mice were vaccinated with 
either PBS or the different H5N1 HA antigens (1µg/mice) with or without a proprietary adjuvant 
(TriAdj) and boosted 21 days after the first immunization. The TriAdj consists of 10 µg poly (I: 
C) (Gibco Life Technologies, Burlington, ON, Canada), 20 µg IDR-1002 (VQRWLIVWRIRK) 
(Genscript), and 10 µg PCEP (Idaho National Laboratory, Idaho Falls, ID, USA). Nine days post 
boost, 3 animals per group were euthanized, and the spleens were collected, while the remaining 
8 mice per group were transferred into the Biosafety Level 3 containment and challenged 
intranasally with 103 pfu of AB14 (H5N1) virus per mouse. Mice were monitored for body weight 
and clinical scores daily after the viral challenge. On day 5 post challenge, 4 mice from each group 
were euthanized, and lungs, spleens were collected. The remaining mice were either humanely 
euthanized when they lost over 20% of their initial weight or euthanized when the animal 
experiment was terminated 14 days post viral challenge. 
3.3.6 Enzyme-linked immunospot (ELISPOT) 
Murine IFN γ or IL-5 specific monoclonal antibodies (Southern Biotech, Birmingham, AL, 
USA) were coated on the ELISPOT plates (Millipore) overnight at 4˚C. Splenocytes collected after 
boost were added at a concentration of 107 cells/ ml along with the stimuli of medium alone, 
purified mammalian H5N1 HA protein (1 g/l), purified bacterial H5N1 HA protein (1 g/l) or 
Concanavalin A (Con A), and incubated overnight at 37 ˚C. Spots were developed using 
biotinylated rat anti-mouse IFN γ or IL-5 antibodies (BD Pharmingen, San Jose, CA, USA), 
followed by visualizing with Alkaline Phosphatase (AP) Streptavidin (Jackson ImmunoResearch, 
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West Grove, PA, USA) and SIGMAFAST BCIP/NBT (Sigma). The developed spots were counted 
with the ELISPOT reader (AID, Strassberg, Germany). 
3.3.7 Virus isolation and titration 
The mouse lung was homogenized in MEM with Penicillin-Streptomycin (Gibco) by 
TissueLyser II (Qiagen) at 25 Hz for 5 minutes immediately. After homogenization, tissues were 
subjected to centrifugation, the supernatant was collected and stored at -80°C for viral titration. 
Virus titre was quantified by 50% tissue culture infectious dose (TCID50) assay. In 96-
well plates, the supernatant of homogenized tissue samples was incubated with the monolayer of 
MDCK cells for 1 hour. After 1 hour of incubation, the inoculum was replaced with MEM 
containing 0.2% BSA and 1 µg/ml TPCK-trypsin (Sigma). The cytopathogenic effect (CPE) 
development was observed with microscopy every 24 hours after infection. The TCID50 titre of 
each sample was calculated by the Spearman & Kärber algorithm (Kärber, 1931; Spearman, 1908). 
3.3.8 RNA extraction and quantitative RT-PCR (qRT-PCR) 
Tissue samples were immediately preserved in RNA later (Qiagen) following tissue 
collection. RNA was extracted by homogenizing the tissues in TRIzol (Invitrogen) using a 
TissueLyser II (Qiagen). The downstream processing was conducted according to the 
manufacturer’s instruction.  
qRT-PCR was performed to determine the cytokine and chemokine gene expression levels 
in tissues of vaccinated and virus challenged mice as previously described with modification (Y. 
Lu et al., 2019). Briefly, 500 µl of RNA was reverse transcribed to cDNA with oligo (dT) and 
SuperScript III Transcriptase (Invitrogen, Carlsbad, CA, USA); qPCR was conducted with gene-
specific primers on a StepOnePlusTM Real-Time PCR system (Applied Biosystems, Foster City, 
CA, USA) with the Power SYBR Green PCR Master Mix (Applied Biosystems). GAPDH was 
used as the housekeeping gene to normalize the mRNA levels of cytokines or chemokines. All 
sequences of qPCR primers used in this study are described previously (Y. Lu et al., 2019). 
3.3.9 Enzyme-linked immunosorbent assay (ELISA) 
To detect influenza-specific lgG levels induced by vaccination, ELISA was performed with 
serum samples taken before vaccination, after the first vaccination, and after the boost. Purified 
H5N1 m-HA protein (2.5g/ml) or b-HA protein (2.5g/ml) were used to coat the 96-well plates 
by incubation overnight at 4˚C. Serially diluted serum was added on to the plate and influenza-
specific IgG1 and IgG2a were detected by biotinylated anti-IgG1 and IgG2a antibodies (Southern 
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Biotech). The reaction was developed by adding AP Streptavidin (Jackson ImmunoResearch) and 
p-nitrophenyl phosphate substrate (PNPP) (Sigma), followed by plate reading in a microplate 
absorbance spectrophotometer (Bio-Rad, Hercules, CA, USA) at 405 nm with the reference 
wavelength of 490 nm. 
3.3.10 Hemagglutination inhibition assay (HAI)  
Serum from vaccinated animals was pretreated with receptor destroying enzyme (RDE) 
(Sigma, #C8772) according to the manufacturer’s instruction. The next day 1.5% sodium citrate 
(pH7.2) was added to the serum and the mixture was incubated at 56°C for 30 minutes to inactivate 
the RDE. Next, the serum was treated for 1 hour at 4°C with 50% red blood cells (RBCs) from 
chicken to reduce nonspecific agglutinations. The treated serum was then ready to be used for the 
assay. The serum was serially diluted by two-fold and incubated with 4 HA units of the H5N1 
virus for 30 min at room temperature. After incubation, an equal volume of 0.5% chicken RBCs 
was added to the wells and incubated for 30 min. The HAI titre of the serum sample was 
determined as the minimum reciprocal dilution of serum to inhibit hemagglutination. 
3.3.11 Ethics statement 
All animal procedures were approved by the University Animal Care Committee (UACC) 
and Animal Research Ethics Board (AREB) of the University of Saskatchewan on 15 July 2018 
(Animal Use Protocol #20170002) in accordance with the standards stipulated by the Canadian 
Council on Animal Care. 
3.3.12 Statistical analysis 
Statistical analysis was performed using GraphPad Prism 7. The difference within all 
groups was examined by one-way ANOVA using the Tukey test. When the difference was 
compared between groups, two-way ANOVA followed by the Tukey post-test was used to obtain 
the P-value. Data are shown as the mean plus standard deviation (SD) of each sample performed 





3.4.1 Expression and characterization of recombinant HA in mammalian and bacterial 
systems 
To generate the secreted form of AB14 HA (m-HA) from mammalian HEK293T cell 
culture, we deleted the transmembrane domain and the cytoplasmic tail of HA, along with the last 
ten amino acids at the C-terminus of HA. We further replaced the native HA signal peptide with 
that of the tissue plasminogen activator (TPA) to facilitate protein secretion from stably transfected 
cells. In addition, the polybasic amino acids between HA1 and HA2 (RERRRK) were replaced 
with a threonine (T) to avoid unnecessary HA cleavage during the protein production process (Fig. 
1A). For bacterial expression, the same HA codon sequence was used except that the signal peptide 
was removed (b-HA). To facilitate purification, proteins were expressed with a histidine tag at the 
C-terminus (m-HA) or the N-terminus (b-HA) (Figure 3.1A).   
The recombinant HA proteins were purified and characterized by immunoblotting and 
Coomassie Blue staining (Figure 3.1B). The two recombinant HA proteins showed significant 
variations in molecular weight, which can be accounted for by the glycosylation that occurs during 
mammalian expression. The recombinant HA proteins were then subjected to circular dichroism 
spectroscopy (CD) to estimate and distinguish their secondary structure. The CD spectra of m-HA 
under far-UV showed that it consists of 16.5% of -helix and 22.6% of -strand, while that of b-
HA indicated the contents of -helix (16.9%) and -strand (21%) (Figure 3.1C). These are in 
agreement with the secondary structure composition predicted by PSIPRED programs based on 
their amino acid sequences, which suggests m-HA comprised of 16.6% of -helix and 20.4% of 
-strand, whereas b-HA contains18.8% of -helix and 20% of -strand. These data showed that 
m-HA and b-HA contained comparable -helix and -strand contents, suggesting they have 




Figure 3.1 Expression and characterization of recombinant HA in two expression systems. 
(A) Schematic representation of the recombinant H5N1 HA. The polybasic cleavage site on the 
HA gene was mutated by replacing RERRRK with T, and the last 10 amino acids at the C-terminus 
of the HA ectodomain were deleted. SP: signal peptide; TM: transmembrane domain; CP: 
cytoplasmic tail; TPA: tissue plasminogen activator; His12: 12 X Histidine; His6: 6 X Histidine. 
(B) Purified recombinant H5N1 HA proteins from mammalian and bacterial systems. The 
expression of recombinant HA proteins was confirmed by Coomassie Blue staining (left) and 
immunoblotting (right) with the anti-His antibody. (C) Circular dichroism (CD) analysis of the 
recombinant HA protein’s secondary structure. Far-UV CD analysis of the structure of 
recombinant HA proteins, the representative graph displaying the secondary structure composition. 
 
3.4.2 Mammalian expressed H5N1 HA protein formulated with TriAdj induces high levels 
of neutralizing antibody titres 
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 To investigate the immunogenicity and the protective efficacy of the recombinant HA 
vaccines, BALB/c mice were intramuscularly immunized with PBS or 1 µg of the recombinant m-
HA or b-HA antigens formulated with or without TriAdj. Mice were boosted 21 days after the first 
immunization with the respective vaccines. Eleven days after the boost, mice were challenged with 
a lethal dose (LD100) of HPAI H5N1 virus (103 PFU/mice) (Y. Lu et al., 2019) (Figure 3.2A). 
Serum of all mice was collected on day 0, day 21 and day 30 and subjected to HA-specific antibody 
detection by ELISA. After the first vaccination, m-HA/TriAdj tended to induce a higher titre of 
IgG1 compared to pre-vaccination levels (not statistically significant). After the boost, m-HA, m-
HA/TriAdj, and b-HA/TriAdj stimulated a higher level of HA-specific IgG1 in comparison to the 
corresponding levels induced after the first vaccination; m-HA/TriAdj elicited the highest level of 
IgG1 (Figure 3.2B). Mice immunized with TriAdj-formulated m-HA or b-HA produced increased 
levels of IgG2a after the first vaccination, which further increased following the boost with 
significantly higher levels of IgG2a in the m-HA/TriAdj group (Figure 3.2C) compared to the 
control group. At the two time points tested, b-HA alone did not induce any antibody response; In 
contrast, m-HA/TriAdj elicited the highest and comparable levels of IgG1 and IgG2a antibodies 
(Figure 3.2B and C).  
Serum HAI titre is widely used in the evaluation of anti-influenza antibody response and 
vaccine immunogenicity (R. J. Cox, 2013; Ting Hui et al., 2019; Y. Wang, Wu, et al., 2017). Mice 
vaccinated with a single dose of any of the HA vaccines did not result in significantly higher HAI 
titres over pre-vaccination (Figure 3.2D).  However, after the boost, m-HA/TriAdj induced a HAI 







Figure 3.2 Humoral immune responses induced by recombinant HA vaccines. 
(A) The timeline and grouping of the vaccination and challenge study in mice. Mouse serum was 
collected before the first vaccination (day 0), before the boost (day 21) and 9 days after boost (day 
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30). The HA-specific serum IgG1 (B) and IgG2a (C) titres were determined by ELISA. Serum 
HAI titre was determined by using the AB14 virus (D). Data are shown as the mean ± standard 
deviation (SD). Significant differences are denoted by two-way ANOVA using the Turkey test. 
*(P < 0.05), ** (P < 0.01), or *** (P < 0.001).   
 
3.4.3 Mammalian expressed H5N1 HA protein formulated with an adjuvant produces high 
numbers of IFN-γ and IL-5 secreting cells 
To assess the ability of the HA vaccines to induce cell-mediated immune responses after 
vaccination, splenocytes were isolated from vaccinated and control mice 9 days after the boost, 
and antigen-specific responses were measured by IFN γ and IL-5 ELISPOT assays. Both m-HA 
and b-HA antigens formulated with TriAdj were able to induce significantly more numbers of 
antigen-specific IFN γ-secreting cells than the control group (Figure 3.3A). In contrast, the 
numbers of IL-5 producing T cells increased drastically only in the mice vaccinated with m-
HA/TriAdj (Figure 3.3B).  
Collectively, the results demonstrated that TriAdj formulated m-HA vaccine consistently 
elicited significantly higher titres of antigen-specific IgG1, IgG2a, and HAI; in addition, m-




Figure 3.3 Cell-mediated immune responses elicited by recombinant HA vaccines. 
Spleens were collected 9 days after boost. The number of IFN γ (A) and IL-5 (B) secreting T cells 
per 106 splenocytes was assessed by ELISPOT. The number of spots observed in wells stimulated 
only with medium was counted and subtracted as background. Results are reported as the number 
of IFN γ- or IL-5- secreting cells per 106 splenocytes when stimulated with either m-HA or b-HA 
antigens. SFC: spot-forming cells. Data are shown as the mean ± standard deviation (SD). 
Significant differences are denoted by one-way ANOVA using the Turkey test. *(P < 0.05), ** (P 
< 0.01), or *** (P < 0.001). 
 
 
3.4.4 Mammalian expressed H5N1 HA protein with the TriAdj completely protects mice 
from the lethal challenge with the HPAI H5N1 virus 
To evaluate the protective effect induced by the recombinant HA antigens, mice that 
received two vaccine doses were challenged with an LD100 of HPAI H5N1 virus (103 PFU/mice) 
(Figure 3.2A). All mice that received m-HA/TriAdj survived the lethal viral challenge. During the 
first 3 days after virus challenge, mice in this group only showed marginal body weight loss with 
no disease signs and started gaining weight on day 4 post challenge. In contrast, mice immunized 
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with the other vaccines and challenged with H5N1 virus experienced rapid weight loss greater than 
20% of their initial body weight within 7 days; they all reached the humane endpoint by exhibiting 
severe illness signs such as rough coat, hunched posture and were no longer mobile. These mice 
did not survive the duration of the trial (Figure 3.4A and B). Consistent with these results, 
infectious virus could not be detected in the lung of the mice that received m-HA/TriAdj, whereas 
mice immunized with either PBS, m-HA, b-HA or b-HA/TriAdj had a lung virus titre of 2.87x106 
TCID50/g, 2.08x106 TCID50/g, and 1.42x106 TCID50/g, respectively on day 5 post challenge 
(Figure 3.4C).  
 
Figure 3.4 Body weight, survival rate and lung viral titre of mice. 
Mice received different vaccines and were challenged intranasally with AB14 (H5N1) virus (103 
PFU/mice). The body weight changes (A) and the survival rates (B) were monitored. The virus 




To access the pathological immune responses induced by H5N1 virus infection after 
vaccination, we determined RIG-I receptor and cytokine gene expression levels in lung tissue of 
mice on day 5 post challenge by qPCR (Figure 3.5). RIG-I is a major pattern recognition receptor 
that recognizes the influenza virus infection and activates the interferon responses (G. Liu et al., 
2018; Loo & Gale, 2011; Opitz et al., 2007). RIG-I mRNA was significantly upregulated in PBS 
vaccinated and H5N1 virus challenged mice; in contrast, the m-HA/TriAdj vaccinated and virus 
challenged mice had the lowest RIG-I gene expression compared to all other groups. The gene 
expression of both type I interferons (IFN ɑ and IFN β), type II interferon IFN γ, and interferon-
gamma-inducing protein 10 (IP-10) was significantly up-regulated in PBS vaccinated and H5N1 
virus challenged mice; however, vaccination with m-HA/TriAdj mostly abrogated the up-
regulation of IFNs that occurred following challenge with virus. Similarly, the gene expression of 
proinflammatory (TNF ɑ, IL-6) and anti-inflammatory (IL-10) cytokines was significantly lower 
in the m-HA/TriAdj vaccinated group than in all the other vaccinated groups after virus challenge, 







Figure 3.5 Innate immune receptor, cytokine and chemokine gene expression profiling 
induced by AB14 challenge after mice received two doses of vaccines. 
mRNA levels of the indicated genes in mouse lung on day 5 post challenge (n = 4 mice per virus 
group) were measured by qRT-PCR. Each sample was tested in triplicates. Data are shown as the 
mean ± standard deviation (SD). Significant differences are denoted by one-way ANOVA using 




3.5 Discussion and conclusion 
In the current study, we evaluated the immunogenicity and protection of mice from H5N1 
virus lethal challenge by immunization with the recombinant HA proteins expressed in a bacterial 
system and a mammalian system, with or without an adjuvant. Although bacterial expressed HA 
protein showed a similar secondary structure to that of mammalian expressed HA as determined 
by CD spectroscopy, bacterial expressed HA alone did not induce any antibody response. Addition 
of TriAdj to bacterial expressed HA led to increased production of serum IgG; however, it had no 
HAI activity. Vaccination with m-HA without adjuvant induced elevated levels of both antibody 
and cellular immune responses after the boost. However, this was insufficient to provide protection 
from a lethal dose infection of the H5N1 virus. These results suggested that H5 HA alone is a poor 
immunogen and that proper glycosylation is required to induce neutralizing antibodies. This 
finding is in agreement with the previous report that MDCK and Vero cell-derived glycovariants 
could affect T-cell activation and cytokine production; removal of glycosylation dramatically 
decreased HA-specific antibody titre (Hutter et al., 2013). 
Formulation of TriAdj with mammalian expressed HA led to increased levels of both IgG1 
and IgG2a antibodies after the first vaccination; these levels further rose after the boost. 
Additionally, induction of virus-specific neutralizing serum antibodies measured by HAI, and an 
increased number of Th1-associated IFN γ secreting- as well as Th2-associated IL-5 secreting- T 
cells only occurred in mice vaccinated with m-HA/TriAdj (R. M. Talaat, Mohamed, Bassyouni, & 
Raouf, 2015; Viallard et al., 1999). These data suggested that the m-HA/TriAdj vaccine induced 
balanced Th1 and Th2 immune responses with effective humoral immunity. These immune 
responses were clearly attributable to the TriAdj, and our challenge study showed that these 
immune responses provided complete protection to the lethal H5N1 virus challenge in mice. 
TriAdj is comprised of three components: poly(I:C), host defense peptide, and 
polyphosphazene. Poly(I:C) is recognized by TLR3 and other intracellular innate immune 
receptors. Activation of these receptors triggers the production of pro-inflammatory cytokines, 
which will activate the immune cells, such as monocytes/macrophages, DCs, natural killer cells, 
B cells and T cells (Stahl-Hennig et al., 2009; Trumpfheller et al., 2008; Trumpfheller et al., 2012). 
The host defense peptide IDR-1002 is immunomodulatory and promotes the induction of multiple 
cytokines and chemokines, including CCL1, CCL2, CCL5, and IFN γ, and the recruitment of 
neutrophils and monocytes, resulting in the enhancement of the immune responses against 
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pathogens (Nijnik et al., 2010; Prame Kumar, Nicholls, & Wong, 2018). The third component, 
PCEP, is a synthetic water-soluble polymer. It allows multimeric presentation by forming a 
complex with the other two components and antigen through non-covalent interaction, thus 
enhancing the stability, immunogenicity of the antigen (Awate et al., 2012; Garg, Babiuk, van 
Drunen Littel-van den Hurk, & Gerdts, 2017; Mutwiri et al., 2007). Previous studies from our 
group have shown that large and small animals vaccinated with viral subunits formulated in TriAdj 
demonstrate effective protection against challenge with a balanced response and that the immunity 
is long-lasting (Garg et al., 2018). 
Formulation of TriAdj with subunit vaccine stimulated the induction of T follicular helper 
cells, plasma cells, and memory B cells after intranasal immunization (Garg, Babiuk, et al., 2017). 
Mucosal immunization with TriAdj formulated subunit RSV vaccine elicited potent antigen-
specific mucosal and systemic immune responses, which provided protection of RSV infection in 
cotton rats (Garg et al., 2018). Given the advantages of intranasal vaccination, future studies will 
look at the effectiveness of immunizing animals intranasally with m-HA/TriAdj. In addition, with 
the induction of a balanced Th1 and Th2 response and the high neutralizing antibodies levels 
observed in our study, m-HA/TriAdj vaccine holds the promise to provide broader protection 
against heterologous subtypic H5N1 influenza virus infection. 
In summary, recombinant HA expressed and purified from mammalian cells, and 
formulated with novel adjuvant TriAdj induced robust and balanced immune responses, and it has 
the potential to protect humans against a possible pandemic HPAI H5N1 outbreak. 
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CHAPTER 4 DISCUSSION AND CONCLUSIONS 
Currently, avian influenza viruses have been continuously circulating in birds and 
occasionally caused human infections. The spread of zoonotic HPAI H5N1 virus from poultry to 
humans highlighted its threat to public health. The HPAI H5N1 viruses caused over 50% mortality 
rate in human infection cases.  Fortunately, there is no evidence of interhuman transmission of the 
H5N1 virus to date. (H. Imai et al., 2018; WHO, 2019c). Avian influenza viruses preferably bind 
to α-2, 3-linked sialic acid receptors mostly located on the intestinal epithelial cells of waterfowls 
(Gambaryan et al., 2003; Paulson & de Vries, 2013). However, the highly pathogenic avian H5N1 
viruses adapt the ability to bind to α-2, 6-linked sialic acid receptors on the human upper 
respiratory tract to be efficiently transmitted from poultry to humans (M. Imai & Kawaoka, 2012). 
Human infection cases of avian influenza H5N1 viruses are characterized by multi-organ failure, 
neurological disorders and fulminant pneumonia with acute respiratory distress syndrome (ARDS), 
which is the main reason for H5N1-associated human mortality (de Jong et al., 2006; Li et al., 
2018). Fatal H5N1 human cases are also associated with high nasal virus loads, frequent detection 
of viral RNA in serum, and hyperinduction of proinflammatory chemokines and cytokines in the 
lung (de Jong et al., 2006; Westenius, Makela, Julkunen, & Osterlund, 2018).   
Ever since the first human infection cases of HPAI H5N1 virus in 1997 in Hong Kong, the 
HPAI H5N1 viruses have spread to multiple countries. In 2014, A/Alberta/01/2014 (H5N1) (AB14 
(H5N1)) virus was isolated from a Canadian traveler shortly after returning from China (Maurer-
Stroh et al., 2014; Pabbaraju et al., 2014). This particular strain jumped from avian to human due 
to several mutations on the receptor binding site of the HA gene in the AB14 (H5N1) virus 
(Pabbaraju et al., 2014). We identified the pathogenicity of this particular Canadian isolate of 
HPAI H5N1 virus in a mouse model. We found that the AB14 (H5N1) virus could result in high 
mortality in mice with the induction of systemic infections as well as dysregulation of pro-
inflammatory cytokines and chemokines in multiple organs without further adaptation (Y. Lu et 
al., 2019). These data not only provide a more thorough understanding of this human case report 
of HPAI H5N1 virus, but also provide a valuable animal model for vaccination studies against this 
AB14 (H5N1) virus.  
In this study, after HPAI AB14 (H5N1) challenge, virus particles were detected in mouse 
lung, spleen and brain tissue. The mechanism of influenza associated spleen infection is not known. 
One possible explanation is that there is a period of viremia upon severe lung inflammation (Tse 
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et al., 2011; X. Wang, Tan, Zhao, Ye, & Hewlett, 2014). Alternatively, viral particles or antigens 
may migrate to the spleen with phagocytes or antigen-presenting cells. In the context of HPAI 
H5N1 virus-induced central nervous system infection in the brian, it has been reported that some 
laboratories confirmed that human HPAI-infected cases had H5N1 virus or viral RNA isolated 
from the brain tissues, serum and cerebrospinal fluid (de Jong et al., 2005; Gao et al., 2010; Mak 
et al., 2018). Moreover, administration of 106 50% egg infectious doses in ferrets via the upper 
respiratory tract induced high viral loads in the cerebrum, suggesting that HPAI H5N1 virus has 
the ability to cause systemic infection in animal models (Edenborough et al., 2016). My research 
also indicated that this particular HPAI H5N1 human isolate (AB14) is capable of replicating 
systematically and reaching high viral loads in the brain after challenge with 103 PFU of the virus 
(Y. Lu et al., 2019).  
Animal models of influenza play an essential role in viral pathogenicity studies and in pre-
clinical vaccination studies (Margine & Krammer, 2014; Oh & Hurt, 2016). We established the 
model in mice due to the following factors: low experimental cost, large animal numbers per 
experiment, and easy handling process (Marjuki et al., 2014; Zarogiannis et al., 2012). We’ve 
evaluated the viral pathogenicity through the observation of the virus-induced weight loss, 
mortality in mice and through the measurement of viral titers and proinflammatory cytokine 
upregulations in different murine organs post challenge. However, the biggest limitation of using 
a mouse influenza model is the lack of clinical symptoms in mice after infection (Oh & Hurt, 2016).  
In contrast to the mouse influenza model, ferrets could display comparable clinical 
symptoms, such as elevated body temperatures, sneezing, and nasal discharges, to that of humans 
after influenza infection (Gooch et al., 2019; Maines et al., 2006). Furthermore, the ferret influenza 
model also serves as an ideal approach to display the transmission ability of influenza viruses, 
because influenza viruses could efficiently infect ferrets without further adaptations (Belser et al., 
2018). The superior advantages of the ferret influenza model are that ferrets and humans share 
similar lung physiology, including similar distribution of sialic acid receptors for influenza viruses 
in the respiratory tract (van Riel et al., 2007; Zeng et al., 2013). However, there are some 
limitations about using the ferret model; these include relatively small animal group sizes due to 
the high experimental cost and facility requirement and lack of available immunological reagents 
(Enkirch & von Messling, 2015). Currently, ferret models have been used in viral susceptibility 
and transmission studies, and as a pre-clinical model to study influenza infection in particular age 
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groups including young children, the elderly or immunocompromised individuals (Huang et al., 
2012; Paquette et al., 2014; Q. Zhang et al., 2013). 
After the establishment of a mouse HPAI H5N1 disease model, we aimed to develop of a 
pre-pandemic subunit H5N1 vaccine. The preparation for pandemic vaccine stock could not only 
counteract a potential pandemic, but are also recommended by CDC for all laboratory workers 
working on developing influenza vaccines against the HPAI H5N1 viruses (Centers for Disease, 
Prevention, Gangadharan, Smith, & Weyant, 2013). Due to the weak immunogenicity  of the HA 
antigen of the H5N1 virus, the subunit vaccine with HA antigen alone did not elicit strong immune 
response (Pitisuttithum et al., 2017). To strengthen the immunogenicity of the subunit influenza 
vaccine, increased antigen doses, the use of adjuvants, or the application of prime and boost 
strategy are used in H5 vaccines (Karron et al., 2009; K. R. Talaat et al., 2014; Treanor, Campbell, 
Zangwill, Rowe, & Wolff, 2006; Y. Wang, Wu, et al., 2017). Research showed that adjuvanted 
plant-derived recombinant HA of H5N1 induced high levels of antigen-specific IgG titres in the 
serum and IgA titres in bronchial secretions in mice (Ting Hui et al., 2019). Besides that, the 
recombinant HA H5N1 vaccine also elicited cell-mediated immunity and provide full protection 
against challenge with a lethal dose of H5N1 virus in ferrets (S. H. Wang et al., 2019). The 
application of a subunit influenza vaccine is an effective and economical option comparing to 
conventional vaccines. 
The subunit influenza vaccine we developed in this project contained recombinant HA 
antigens expressed in both mammalian and bacterial systems to obtain the distinct protein 
glycosylation statuses. A mammalian expression system allows both N-linked and O-linked 
glycosylation of the secreted protein, especially cell line 293-based platforms, and is capable of 
providing closer post-translational modification processes and functions to protein naturally 
produced in human cells (P. J. Kim, Lee, & Jeong, 2009; Walsh, 2010). This system also allows 
easy transfection and abundant protein secretion, which will reduce the production course, simplify 
the harvesting process, and increase the production amount, whereas the bacterial protein 
expression system only provides incomplete glycosylation to expressed proteins but produces a 
large quantity of recombinant protein (R. Chen, 2012). These studies correlated with the data we 
obtained. The recombinant HA protein expressed in mammalian 293T cells but not in E. coli has 
a substantially larger size than the calculated mass of the unmodified protein when identified by 
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Coomassie blue staining, demonstrating the distinct post-modification modification process in a 
mammalian expression system.  
The use of adjuvants in subunit vaccines could significantly enhance and broaden the 
vaccine immunogenicity, especially in subunit influenza vaccines that showed weaker 
immunogenicity (Awate et al., 2012; Couch et al., 2012). Previous research demonstrated that the 
MF59-adjuvanted influenza subunit vaccine (Fluad) and the inactivated split virion vaccine 
(Vaxigrip) had comparable immunogenicity against the H1N1 and the H3N2 virus strains (Beyer, 
Palache, & Osterhaus, 1998; Squarcione, Sgricia, Biasio, & Perinetti, 2003). The adjuvant we used 
in this research is a VIDO patented adjuvant, TriAdj, comprised of three major components, 
poly(I:C), a host defense peptide, and PCEP (Garg et al., 2014; Mutwiri et al., 2007; Niyonsaba et 
al., 2013). combination of the three components was tested in vivo in different animal models with 
various viral antigens (Garg, Brownlie, et al., 2017; Garg et al., 2018; Garg et al., 2019; Sadat et 
al., 2017). The TriAdj has been shown to significantly enhance the immune responses when co-
formulated with viral or bacterial antigens of infectious diseases including some respiratory viral 
antigens, such as RSV (Garg et al., 2014). Similarly, our results demonstrated that the adjuvanted 
recombinant HA subunit vaccine (m-HA/TriAdj) could induce high levels of antigen-specific 
antibodies and provide complete protection against H5N1 viral infection. 
One of the major components of the TriAdj, poly(I:C) have been shown to induce cell-
mediated immune responses with H9 antigen against heterologous infection in ducks (A. Zhang et 
al., 2017). Similar adjuvant effects were observed with varies subtypes of HA antigen in pigs 
(Thomas et al., 2015). In mice, poly(I:C) was reported to enhance both mucosal responses and 
humoral responses in mice when co-formulated with inactivated H5N1 virus and administrated 
intranasally. These data provide insights of poly(I:C) as an adjuvant is capable of inducing both 
humoral and cell-mediated immune responses and generating heterologous protection in ducks and 
pigs. The other two components of the TriAdj are both able to upregulate the production of pro-
inflammatory cytokines and chemokines in injection site (Awate, Eng, Gerdts, Babiuk, & Mutwiri, 
2014; Prame Kumar et al., 2018). Moreover, PCEP activates naïve B cell directly and generates 
antigen-specific T cell responses (Awate et al., 2014; Awate et al., 2012). Previous study showed 
that the combination of TLR agonist, IDR, and PCEP is capable of developing balanced immune 
responses after intramuscular vaccination and enhancing mucosal immunity when administrated 
intranasally (Kindrachuk et al., 2009; Kovacs-Nolan, Latimer, et al., 2009; Kovacs-Nolan, 
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Mapletoft, Latimer, Babiuk, & Hurk, 2009). Poly(I:C), IDR, and PCEP alone as vaccine adjuvant 
induces moderate immune responses, while the combination of the displayed strong immune 
responses by enhancing the DC maturation followed by cytokines and chemokines expression 
(Garg et al., 2014; Snider, Garg, Brownlie, van den Hurk, & van Drunen Littel-van den Hurk, 
2014). The relative low cost and significant efficacy of the TriAdj make it an ideal adjuvant 
candidate to administrate with multiple viral antigens.  
Besides the vaccine adjuvants, the distinct glycosylation profiles of HA antigens in the 
vaccine also results in the varied antigenicity. It was reported that specific N-glycosylation sites 
on HA masked the antigenic epitopes and affected the antigenicity of the virus (W. Wang et al., 
2010). Moreover, the distinct influenza HA N-glycosylation caused by the production of 
recombinant viruses in different cells lines resulted in remarkably different immunogenicity in 
vivo. T cell activation was significantly diminished after the stimulation of deglycosylated variant 
compared with fully glycosylated protein, which indicates the essential role of N-glycosylation on 
HA for immunogenicity. Another study using recombinant HA expressed in mammalian or insect 
cells showed that HA carrying complex glycan structures or single N-acetylglucosamine residues 
induces higher neutralizing antibodies titres than HA carrying high-mannose glycan structures (R. 
P. de Vries et al., 2012). Our results demonstrated that the HA produced in mammalian cells, which 
carries complex glycan structures, exhibited higher levels of neutralizing antibody and more 
balanced Th1 and Th2 immunity compared to non-glycosylated HA. In contrast, the non-
glycosylated HA induced a Th1-biased immune response with low induction of neutralizing 
antibodies. Furthermore, fully glycosylated HA with TriAdj but not non-glycosylated HA 
completely protected mice from lethal infection of the homologous virus, indicating the enhanced 
protection may be provided by glycosylation of the HA antigen.  
In this study, we used the intramuscular delivery route for the recombinant subunit H5N1 
influenza vaccine. Besides the intramuscular (IM) injection, the most comment routes are 
intradermal (ID) injection and intranasal spray. Due to the varied distribution of immune cells in 
the tissue, blood, mucosal membrane, and skin, different vaccine delivery routes could result in 
distinct vaccine efficacy (Chaplin, 2006).  
ID delivery of 9 µg of a trivalent inactivated HA vaccine showed similar humoral and 
cellular immune responses to IM delivery of 15 µg of a trivalent inactivated HA vaccine in healthy 
adults; it reached similar seroconversion rate three months after vaccination in HIV-1-infected 
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adults. This indicates that ID delivery of influenza vaccine is superior to that of IM delivery 
(Ansaldi et al., 2012; Nougarede et al., 2014). The possible reason for this may be that the DCs 
are predominantly in the dermis (Belyakov, Hammond, Ahlers, Glenn, & Berzofsky, 2004; D. 
Chen et al., 2001). The DCs in the skin could facilitate the capture and presentation of antigens, 
the induction of DC maturation, and the migration of matured DC into draining lymph nodes 
(Bonnotte et al., 2003).  
Apart from IM and ID delivery of influenza vaccine, needle-free intranasal influenza 
vaccines have been used in the market since 2013 for 2-49 years old recipients, which is  a smaller 
range of recipients than that targeted by intramuscularly administrated annual influenza vaccines 
(R. J. Cox, 2013). The IN delivery route of influenza vaccine induces both systemic and local 
immunity, which could prevent influenza infection and transmission (L. Zhang, Wang, & Wang, 
2015). Although the FluMist®, a live-attenuated intranasal trivalent influenza vaccine, induced 
significantly lower levels of HAI titres, which is incomparable to the injectable influenza vaccine, 
it stimulated greater levels of local IgA antibody and had similar efficacy against culture-positive 
influenza infections (Beyer, Palache, de Jong, & Osterhaus, 2002).  
In summary, the two parts of this thesis established a mouse disease model for HPAI AB14 
(H5N1) virus and developed a vaccine candidate with high efficacy against HPAI H5N1 virus. 
Understanding the disease progression of HPAI H5N1 virus in mice and identification of a 
potential anti-H5 vaccine candidate would provide insights into the development of a pandemic 
influenza vaccine and eventually mitigate the threat of pandemic outbreaks. 
This project has proved that the TriAdj-formulated mammalian HA is capable of inducing 
robust antigen-specific immunity in mice and protecting mice from homologous H5N1 challenge. 
Based on the current data, our next step would be to identify whether TriAdj-formulated 
mammalian HA vaccination could provide protection against heterologous virus challenge in mice. 
Besides that, we would also broaden the coverage of the vaccine by establishing a ferret model to 
explore the efficacy of the vaccine in vivo, and its potential to prevent viral transmission and 
infection in a ferret model. In the content of vaccine administration route, aside from the current 
IM delivery of the subunit influenza vaccine, the development of the needle-free IN vaccination 
route will be taken into consideration in our future project. In this way, we will better understand 
the immunogenicity, the safety profile, and the protection of TriAdj formulated mammalian HA 
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vaccine, which will all determine whether this novel adjuvanted subunit vaccine could become an 
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